

# GUIDELINES

## Diagnosis and Treatment of Primary Lymphedema Consensus Document of the International Union of Phlebology (IUP)-2013

B. B. LEE, M. ANDRADE, P. L. ANTIGNANI, F. BOCCARDO, N. BUNKE, C. CAMPISI  
R. DAMSTRA, M. FLOUR, I. FORNER-CORDERO, P. GLOVICZKI, J. LAREDO, H. PARTSCH  
N. PILLER, S. MICHELINI, P. MORTIMER, E. RABE, S. ROCKSON, A. SCUDERI  
G. SZOLNOKY, J. L. VILLAVICENCIO

**EDITORIAL COMMITTEE.**— **Chairman: Byung-Boong (B.B.) Lee, MD, PhD, FACS** Professor of Surgery and Director, Center for Vein, Lymphatics, and Vascular Malformation, Division of Vascular Surgery, Department of Surgery, Georgetown University School of Medicine, Washington DC, USA; **Members: Mauro Andrade, MD, PhD** Associate Professor of Surgery, Department of Surgery, University of São Paulo Medical School, São Paulo, Brazil; **Pier Luigi Antignani MD, PhD** Professor of Angiology, Vascular Center, Villa Claudia, Rome, Italy; **Francesco Boccardo, MD, PhD** Assistant Professor of Surgery and Director, Unit of Lymphatic Surgery, Dpt. of Surgery, Section of Lymphology and Microsurgery, University Hospital “S. Martino”, University of Genoa, Genoa, Italy; **Nisha Bunke Paquette, MD, FACPh** Assistant Professor, Section of Endovascular and Vascular Surgery University of California, San Diego; **Corradino Campisi, MD, PhD** Professor of Surgery and Director, Operative Unit of Lymphatic Surgery, Dpt. of Surgery, Section of Lymphology and Microsurgery, University Hospital “S. Martino”, Genoa, Italy; **Robert J Damstra, MD, PhD** Dermatologist, Department of Dermatology, Phlebology and Lympho-vascular Medicine, Nij Smellinghe hospital, Drachten, Netherlands; **Mieke Flour, MD** Dermatology Department, Vascular Centre, Multidisciplinary Diabetic Foot Clinic, University Hospital Leuven, Leuven, Belgium; **Isabel Forner-Cordero, MD, PhD** Lymphedema Unit, Rehabilitation Department, Hospital Universitario La Fe, Valencia, Spain; **Peter Gloviczki, MD, FACS** Joe M. and Ruth Roberts Professor of Surgery, Mayo Clinic College of Medicine, Chair, Division of Vascular and Endovascular Surgery, Director, Gonda Vascular Center, Mayo Clinic, Rochester, MN, USA; **James Laredo, MD, PhD, FACS** Associate Professor of Surgery, Co-Director, Center for Lymphedema and Vascular Malformation, Division of Vascular Surgery, Department of Surgery, George Washington University School of Medicine, Washington DC, USA; **Sandro Michelini, MD** President of the European Society of Lymphology, Chief of Department of Vascular Rehabilitation San Giovanni Battista Hospital, Rome, Italy; **Peter Mortimer, MD, FRCP** Professor of Dermatological Medicine, Clinical Science Division (Dermatology) St George’s, University of London, London, UK; **Hugo Partsch, MD** Professor of Dermatology, Emeritus Head of the Dermatological Department of the Wilhelminen Hospital, Vienna, Austria; **Angelo Scuderi, MD** Santa Lucinda Hospital (Sorocaba – Brazil) – Pontifical Catholic University of Sao Paulo, Brazil. President of UIP (2011-2015); **Gyozo Szolnoky, MD, PhD** Assistant Professor, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary; **Neil Piller, PhD** Professor of Lymphology, Advanced Studies Coordinator, MD program, Director Lymphoedema Research Unit, Department of Surgery, School of Medicine Flinders University and Flinders Medical Centre, Adelaide, South Australia; **Eberhard Rabe, MD** Professor of Dermatology, Phlebology and Dermatologic Angiology, Department of Dermatology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany; **Stanley Rockson, MD** Allan and Tina Neill Professor of Lymphatic Research and Medicine, Director of the Stanford Center for Lymphatic and Venous Disorders, Chief of Consultative Cardiology, Stanford University School of Medicine, Stanford, CA, USA; **J. Lionel Villavicencio, MD, FACS** Distinguished Professor of Surgery, Department of Surgery, Uniformed Services University School of Medicine, and Director Emeritus Venous and Lymphatic Teaching Clinic, Walter Reed Army Medical Center, Bethesda, MD, USA

### PROLOGUE

A huge lymphedematous limb in the status of elephantiasis with recurrent lymphangitis that I encountered on the first day of internship was my first contact with the vascular pathology. Since then chronic lymphedema has remained my major interest throughout my career as a vascular surgeon with great debt to Professors Carlos Mayall and Mario Degni, two of the greatest Brazilian masters of Lymphology world, I studied since my surgery residency. Therefore, this unique Consensus has a special meaning to me as a pupil of assiduous studies of the lymphatic system disorders.

This consensus of the UIP on the Primary lymphedema is the refinement of one previously published and shown during the congress of the chapter in Prague in 2011. Some aspects of lymphedema, for example, elephantiasis, were included in this updated version. The modern methodology based on Evidences, recommended by Guyatt et al <sup>1,2</sup>, was used, taking into account the experience of the authors and publications, and especially those comparative studies of good quality.

As a multifaceted disease in its etiology and pathophysiology, the treatment and control also present a corresponding richness.

This set of recommendations now published definitely demystifies the concept that the “Lymphedema has no cure” or “There’s nothing to do” used by many doctors, including specialists, to declare the state of their patients with lymphatic pathology. As Prof. Mayall used to say, “The most difficult disease to be treated is not the lymphedema but the prejudice and ignorance that dwells in the minds of many physicians”.

I hope that this phenomenal work will help demystify in definitive the concept that “Lymphedema has no cure” and also remind everyone that the lymph vessels do exist and have an important role in the circulation and it should be respected.

I am proud to have been able to participate in this consensus as the UIP President and also as a collaborator.

I congratulate Professor BB Lee for the excellent coordination work and also all the contributing authors who helped to produce this excellent document that will surely be consulted and quoted by several colleagues and for a long time.

ANGELO SCUDERI M.D.  
*President of UIP*

**Primary lymphedema can be managed effectively as a form of chronic lymphedema by a sequenced and targeted treatment and management program based around a combination of Decongestive Lymphatic Therapy (DLT) with compression therapy, when the latter is desired as an adjunct to DLT. Treatment in the maintenance phase should include compression garments, self-management, including self-massage, meticulous personal hygiene and skin care, in addition to lymphtransport-promoting exercises and activities, and, if desired, pneumatic compression therapy applied in the home. When conservative treatment fails, or gives sub-optimal outcomes, the management of primary lymphedema can be improved, where appropriate, with the proper addition of surgical interventions, either reconstructive or ablative. These two surgical therapies can be more effective when fully integrated with manual lymphatic drainage (MLD)-based DLT postoperatively. Compliance with a long-term commitment to MLD/DLT and particularly compression postoperatively is a critical factor in determining the success of any new treatment strategy involving either reconstructive or palliative surgery. The future of management of primary lymphedema has never been brighter with the new prospect of gene-and perhaps stem-cell oriented management.**

[Int Angiol 2013;32:541-74]

**Key words: Primary lymphedema - Truncular lymphatic malformation - Decongestive Lymphatic Therapy - Reconstructive surgery - Ablative surgery - Compression therapy - Compliance - Gene-oriented management.**

## I. Introduction

### Background

The management of chronic swelling of the limbs, and especially the trunk, due to primary lymphedema remains a challenge for patients and clinicians worldwide. Progress over the past several decades has been significant, both in the diagnosis of, and therapy for, this disabling condition. The International Union of Phlebology invited an expert multidisciplinary panel to convene and arrive at a consensus on the management of patients with primary lymphedema in 2009. The current document represents the update.

The goal of the document is not to overrule previously published expert guidelines from other specialty societies or boards. The charge of the panel was to bring together and evaluate the very best and most commonly used available diagnostic tests and therapies for primary lymphedema, which can ultimately be recommended to clinicians treating patients with this condition worldwide.

TABLE I.—Grading recommendations according to evidence.

Grade of Recommendation/ Description	Benefit vs Risk and Burdens	Methodological Quality of Supporting Evidence	Implications
1A/strong recommendation, high-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs without important limitations or overwhelming evidence from observational studies	Strong recommendation, can apply to most patients in most circumstances without reservation
1B/strong recommendation, moderate quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies	Strong recommendation, can apply to most patients in most circumstances without reservation
1C/strong recommendation, low-quality or very low-quality evidence	Benefits clearly outweigh risk and burdens, or vice versa	Observational studies or case series	Strong recommendation but may change when higher quality evidence becomes available
2A/weak recommendation, high-quality evidence	Benefits closely balanced with risks and burden	RCTs without important limitations or overwhelming evidence from observational studies	Weak recommendation, best action may differ depending on circumstances or patients' or societal values
2B/weak recommendation, moderate-quality evidence	Benefits closely balanced with risks and burden	RCTs with important limitations (inconsistent results, methodological flaws, indirect, or imprecise) or exceptionally strong evidence from observational studies	Weak recommendation, best action may differ depending on circumstances or patients' or societal values
2C/weak recommendation, low-quality or very low-quality evidence	Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced	Observational studies or case series	Very weak recommendations; other alternatives may be equally reasonable

Recommendations in the document are graded according to scientific evidence. The panel adopted the system used by Guyatt *et al*<sup>1, 2</sup>, and the document has two grades of recommendations: Grade 1 (strong) recommendation, which is reserved for those tests or procedures for primary lymphedema, where the benefits clearly outweigh the associated risks and Grade 2 (weak) recommendation, which is reserved for those diagnostic tests or procedures, where the benefits do not significantly outweigh the associated risks. The quality of evidence can be high (A), medium (B), low or very low (C) (Table I).

The document presents contemporary concepts encompassing a broad range of new and old diagnostic modalities and treatment options that are currently available in the management of primary lymphedema. We respect all of the currently available consensus documents, previously prepared by the many national and international societies, addressing all issues related to primary lymphedema. We strongly encourage the review of these expert documents as additional references in addition to this consensus document.<sup>3-6</sup>

This document is not meant to overburden the individual, local or national medical communities with specific recommendations, as these may be impractical to some where there is limited availability and access to the recommended technology. On the other hand, we hope that those with experience, knowledge and expertise beyond that described in this document will continue to offer their input to this living consensus document.

The majority of the available data reviewed in the consensus belong to 2B or 2C, and at best, a small number belong to 1C or 2A. Only a few studies reviewed in this consensus have a strong recommendation based on low-quality or very low quality evidence where the benefits clearly outweigh the associated risks. Because of problems associated with the methodology and quality of supporting evidence obtained from observational studies or case series, these data will be limited to a strong recommendation but may change when higher quality evidence becomes available.<sup>1-2</sup>

With these considerations in mind, we support both manual lymphatic drainage (MLD) based

Decongestive Lymphatic Therapy (DLT)<sup>7-10</sup> as the mainstay of treatment and management of primary lymphedema, and the surgical aspect of primary lymphedema care<sup>11-14</sup>. This should improve the brevity and precision of the document, while balancing the need for in depth analysis, thereby permitting IUP members to exercise the best judgment in choosing a current approach to patients with primary lymphedema.

Although lymphedema is currently defined to be an externally (extrinsic) or internally (intrinsic) generated manifestation of lymphatic system insufficiency and deranged lymph transport<sup>5</sup>, **the future of the diagnosis and classification of primary lymphedema is likely to be determined by the pathophysiology or genetic basis of the underlying condition**<sup>15-18</sup> **which would make the present classification**<sup>19,20</sup> such as congenital /praecox /tarda, unnecessary.<sup>21</sup>

It is our hope that this document will stimulate further inquiry and discussion regarding all aspects of primary lymphedema and that it will form a starting point for future discussions and ultimately become a "living document," where periodic updates and revisions are made incorporating new ideas, technologies, and directions.

### **Pathophysiology. Alteration of lymphatic vessels**

The lymphatic circulation is essential for the drainage of interstitial fluid. Lymph vessels are not only crucial to the recirculation of lymphocytes and proteins, and transport of microorganisms by the lymph, but also to the transport of interstitial fluid to the main blood circulation.<sup>22</sup>

The average human body weighing 65 kg contains 3 L of blood plasma and 12 L of interstitial fluid. Up to 8–12 L of afferent lymph are produced each day, of which 4–8 L of ultrafiltrate are reabsorbed into the bloodstream in the lymph nodes. Lymphatic vessels transport daily 4 L of efferent lymph into the bloodstream via the neck veins.

The concentration of proteins in plasma, interstitial fluid, afferent lymph, and efferent lymph is 70 g/L, 20–30 g/L, 20–30 g/L, and 60 g/L, respectively. The fluid turnover (including the volume of fluid reabsorbed in lymph nodes) reaches up to two-thirds of the total volume of interstitial fluid every 24 hours.<sup>23</sup>

The skin on the lower extremities contains a denser and more extensive network of lymphatic capillaries than the skin of the upper extremities.<sup>24</sup>

Due to orthostatic pressure, lower extremities have higher filtration pressure and influx of fluids, and it is thought that the capacity for lymph transport in the lower extremities is greater, in order to compensate for the higher influx of interstitial fluid caused by the effects of orthostatism and gravity.

Spontaneous contractility of lymphatic vessels is utilized in lymph transport. Regular contractions of lymph vessels, at a frequency of 2–4 per minute, have been observed *in vitro*. Spontaneous contractions of prenodal lymphatic vessels have been observed in human legs, and these contractions were shown to drive the lymph.<sup>25</sup> Internal extensions of lymphatic endothelial cells act as valves and guarantee a one-way lymph flow.<sup>26, 27</sup>

In a steady state, the extravasation of fluids and proteins from blood vessels is balanced by lymphatic drainage and return into the bloodstream.

If microvascular filtration in blood capillaries and venules, as in the case of advanced chronic venous disease (CVD), exceeds the lymphatic drainage for sufficiently long periods, an edema occurs in afflicted areas by accumulation of tissue fluid in the interstitium.

In addition, lymphatic dysfunction and structural damages to lymphatic network are associated with varicose veins, and the subsequent lymph stasis and reduced lymph transportation lead to inflammation.<sup>26</sup> This is associated with lipid accumulation in the media of the diseased veins. Such accumulation of inflammatory lipids in the vein wall might further damage adventitial lymphatic vessels.<sup>26</sup>

## **II. Definition – General Consideration**

Chronic lymphedema is a progressive and a relatively painless swelling of any peripheral tissue – limbs, head and neck, breast, trunk or genitals that is the result of a less-than-optimal transport capacity of the lymphatic system. Chronic lymphedema can be primary or secondary. In patients with **secondary lymphedema** a spe-

cific external cause (filariasis, previous surgery, radiation, malignancy, infection or inflammation, trauma, etc.) that is believed to impact on a presumed previously normally functioning lymphatic system is identified<sup>27-31</sup>. In patients with **primary lymphedema** the cause of decreased lymphatic transport can be an intrinsic "defect"<sup>32-35</sup> or a malfunction of the lymph conducting elements<sup>36-39</sup>, which we believe is due to a genetically determined abnormality of lymphatic anatomy or function.

The preponderance of primary chronic lymphedema represents the clinical expression of heritable abnormal structural development, and defined as a truncular lymphatic malformation (LM)<sup>32, 40</sup>. In these circumstances, a malformation is clinically manifest as a macroscopic structural abnormality, but some primary lymphedemas have very little structural derangement but represent a functional defect that is molecular in origin. Therefore, a malformation may not necessarily have attributes that can be imaged but may ultimately require detection or definition in molecular or other functional terms.

LMs are a common type of congenital vascular malformation (CVM).<sup>41-44</sup> They occur as independent (predominant) malformations or can be combined with other CVMs such as venous malformations (VM)<sup>45-47</sup>, arterio-venous malformations (AVM)<sup>48-50</sup>, and/or capillary malformations (CM)<sup>51, 52</sup>. Combined malformations are classified as hemolymphatic malformations (HLM)<sup>53-55</sup> according to the Hamburg Classification.<sup>56-58</sup>

Primary lymphedema is believed to represent mainly a clinical condition due to truncular malformations of the lymphatic system with lymphatic truncular hypoplasia (89%), aplasia, numerical hyperplasia, or dilation (lymphangiectasia-10%) with valvular incompetence. Selective lymph node dysplasia rarely predisposes an individual to primary lymphedema (eg, ilio-inguinal nodal sclerosis).<sup>59</sup> There is some controversy where some experts believe that all lymphedema and lymphatic malformations are genetically derived and propose to define lymphedema as an abnormality of lymph drainage where the predominant effect is on the tissue territory drained.

Nevertheless, primary lymphedema includes all those manifestations of lymphedema that represent an inherited condition: a disease-causing

mutation of any of the genes involved in the development of the lymphatic system, can result in a familial distribution of primary lymphedema. Representative identified genetic mutations can affect *FLT4*<sup>60-62</sup>, *FOXC2*<sup>16, 61</sup>, and *GJC2*<sup>63, 64</sup>

All these forms of genetically determined lymphedema have a prevalence of 1/6000 to 1/10000 live births and today are collectively classified as "primary" lymphedema.

Such conditions have been reported among multigeneration families where the lymphedema is the major clinical sign as primary phenotype and shows an autosomal dominant pattern of inheritance; various genes strongly associated with this pattern of inheritance have been demonstrated with variable expression and variable age at onset.<sup>38, 60, 65</sup>

Milroy disease is one example of an inherited lymphedema. Many of the family cohorts examined demonstrate a gene mutation at the locus 5q35.3: the gene mutated is *FLT4*, which encodes for the Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) receptor.<sup>15, 60, 65</sup> Milroy disease is an autosomal dominant single gene disorder inherited as a germline mutation, whereas most asymmetrical and regionally limited genetic disorders (e.g. malformations) are due to a somatic mutation. In this situation, some tissue (e.g. skin) may be unaffected while the adjacent tissue (skin) may carry the mutation, an example of "mosaicism."

Although a family history was thought to be a prerequisite for diagnosis of (Nonne) Milroy syndrome (or *FLT4*-related lymphedema), the description of "de novo *FLT4* mutations" in five sporadic patients.<sup>66</sup> ( and incomplete penetrance estimated at 90% ) suggests that *FLT4* inactivating mutations are even found in sporadic cases.<sup>62</sup>

Nevertheless, the 'hereditary' type of primary lymphedema accounts for the minority of cases, while the 'sporadic' type represents the majority although both have a genetic basis (Table II).

There are also various terminologies for this group of lymphedema but we emphasize the term 'primary' in preference to 'essential' or 'idiopathic' as recommended by the ISL consensus document 2009.<sup>4</sup>

There is some concern about the current definition of the primary lymphedemas, as such. In fact, it is very likely that some may represent post-natal obliterations of lymph collectors and

TABLE II.

Single gene disorders associated with Primary Lymphedema	Chromosome/Gene
Milroy disease	VEGFR3
Milroy- like disease	VEGFC
Late onset 4 limb lymphedema	GJC2
Lymphedema-Distichiasis syndrome	FOXC2
Syndromes associated with Primary Lymphedema	
Agenaes syndrome	Not known
Cardio-facio-cutaneous syndrome	KRAS, BRAF, MAP2K1,MAP2K2
CHARGE syndrome	CDH7
Choanal atresia-lymphoedema	PTPN14
Ectodermal dysplasia, anhidrotic,immunodeficiency, osteopetrosis and lymphoedema(OL-EDA-ID syndrome)	IKBKG (NEMO)
Fabry disease	GLA
Hennekam syndrome (Generalised Lymphatic dysplasia)	CCBE1
Hypotrichosis-lymphoedema-telangiectasia	SOX18
Lymphoedema-myelodysplasia (Emberger syndrome)	GATA2
Microcephaly with or without chorioretinopathy, lymphoedema and mental retardation (MCLMR)	KIF11
Noonan syndrome	PTPN11, KRAS, SOS1
Chromosomal abnormalities associated with Primary Lymphedema	
Turner syndrome	45,X0
Phelan McDerimid syndrome	22q terminal deletion Ring chromosome 22
Prader Willi syndrome	15q11 microdeletion Or maternal UPD 15 22q11 microdeletion
Velocardiofacial syndrome	
Lymphatic abnormalities associated with a mosaic genetic defect	
Proteus syndrome	AKT1
Klippel Trenaunay syndrome	
CLOVE/Fibroadipose hyperplasia	AKT pathway
Macrocephaly-capillary-malformation (MCM)	AKT Pathway (PIK3CA)
Primary Lymphedema with unknown aetiology but likely to be genetic	
Meige disease	
Multisegmental lymphatic dysplasia with systemic involvement	

lymph nodes, thus mimicking congenital and prenatal pathology. True malformations, by definition, are present at birth. Although the term 'primary' should indicate an intrinsic defect, there are some lymphoedemas, e.g. ilio-inguinal nodal sclerosis, that are designated as primary because the pathogenesis is not well-understood.

Primary lymphedemas have been historically classified into three groups depending on the age of onset: congenital (before age 2), praecox (between age 2 and 25, but most typically of pubertal onset) and tarda (after age 35). Gender distribution is variable.

There is also some objection to classifying all

lymphedema 'tarda' as a primary disorder on the basis of the conventional spectrum based on the age of the onset. The arbitrary age of 35 used to separate 'tarda' from 'praecox' is not clinically useful because this classification does not imply a mechanism or pathogenesis.

Lymphedema-distichiasis syndrome<sup>67-69</sup> caused by mutations in the *FOXC2* gene is associated with congenital distichiasis (extra eyelashes arising from the Meibomian gland) (95%) and congenital heart disease (8%).but lymphedema never manifests at birth, usually presents in late childhood or puberty and may be delayed until the 5<sup>th</sup> decade.<sup>16</sup> Therefore, terms like tarda and

precox are outdated terms, potentially misleading as sole criteria for classification.

### III. Definition – Special Consideration

#### **Gene Mutation as Etio-pathogenesis of Lymphedema**

The first gene identified as causative for human lymphoedema was *FLT4* (encoding the VEGFR3 receptor) in 1998.<sup>15, 65, 71, 72</sup> This was found to be mutated in some cases of Milroy disease (MD), a congenital onset form of lymphedema with swelling of the feet and lower limbs, but few other associated clinical features.<sup>62</sup> Soon after, the gene for Lymphedema Distichiasis Syndrome (LDS) was mapped and subsequently identified as the developmentally important transcription factor, *FOXC2*.<sup>16, 61, 72, 73</sup> LDS has pubertal onset lymphedema of the lower limbs, but is a syndromic condition where distichiasis (aberrant eyelashes originating from the meibomian glands) and varicose veins are prominent clinical signs, with an increased incidence of congenital heart disease and cleft palate.

Identification of further genes was then a slow process. The extremely rare syndrome Hypotrichosis-Lymphedema-Lymphedema-Telangiectasia syndrome (HLTS) was shown in 2003 to be caused by mutations in *SOX18*<sup>74</sup>, while in 2009, *CCBE1* was identified as the gene underlying autosomal recessive Generalised Lymphatic Dysplasia (also known as Hennekam Syndrome).<sup>75, 76</sup>

Recently, the gene, *GJC2* was discovered by Ferrell *et al.*<sup>63</sup> This codes for connexin 47, and appears to affect gap junctions. The predominant phenotype for mutations in this gene is late onset 4 limb involvement, but there is a wide diversity in age of onset and extent of limb involvement.<sup>77</sup> Two further genes very recently identified are *GATA2* and *KIF11*.<sup>64, 78</sup>

Over the last twelve years, seven genes for human lymphatic disease have been discovered. The identification of more genes is important for several reasons. Their discovery uncovers proteins of significance in the lymphatic developmental pathway, and in the maintenance of lymphatics in the adult. *FOXC2* and *SOX18* are now known to play pivotal roles in lymphangiogenesis, but this was only made apparent after

the identification of their pathogenic role in primary lymphedema.

Recent studies on *CCBE1* have identified it as crucial for lymphangiogenesis.<sup>79</sup> At a clinical level, identification of a mutation confirms the diagnosis and allows full characterisation of the phenotype, e.g., the incidence of congenital heart disease in LDS. The ability to give accurate recurrence risks, provide information about the natural history of the disease, and offer the possibility of prenatal diagnosis to families with severe forms of lymphatic dysplasia, is extremely important. By understanding the mechanism of disease, and in particular the molecular changes in the protein, opportunities are presented for a more targeted treatment.

#### **Clinical Implementation of Genetic Mutation**

Primary lymphedema represents the major clinical sign among *FLT4*-related lymphedema known as Nonne-Milroy syndrome (Milroy disease) and in *FOXC2*-related lymphedema known as Lymphedema-distichiasis syndrome. But in other disorders, the lymphedema may remain a minor clinical manifestation within a complex syndrome in which other abnormalities dominate the clinical presentation, e.g. involving the liver (e.g., Cholestasis-lymphedema syndrome)<sup>80</sup>, bone marrow (e.g. Emberger syndrome)<sup>64</sup>, or gut pathology and developmental delay (e.g. Hennekam syndrome).<sup>75</sup>

Not all gene mutations will result in a phenotype that reflects a major impact on lymphatic function. A minor impact among patients with primary lymphedema has been also reported for *HGF* and *MET* genes,<sup>81</sup> representing a simple association between some nucleotide changes and lymphedema phenotype. Each mutation (four in the *HGF* and two in the *MET* gene) was found in only one proband; two of these probands had lymphedema and lymphangiectasia.

Due to incomplete penetrance, some individuals of the same family can remain as (healthy) carriers of the genetic mutation and do not develop the disease. Several non-identical conditions can be associated with the lymphedema. These phenomena are closely associated with the activity of (unknown) modifier genes that act according to a model of genetic susceptibility.<sup>16</sup>

However, when the mutation results in defec-

tive development to varying degrees, the individual is no longer a 'healthy' carrier. Within some families, the lymphoscintigraphy shows various loco-regional lymph transport abnormality in healthy looking limbs, suggesting defective development even in the absence of edema. This 'sub-clinical' condition of lymphedema suggests the potential risk of such varying degrees of developmental error to trigger clinically significant lymphatic transport insufficiency later in the life when the triggering conditions are met. This unique group of subclinical presentation merits special consideration in the realm of lymphedema prevention.

Secondary lymphedema includes all those manifestations of lymphedema occasioned by acquired lymph transport abnormalities and, hence, triggered by an external event such as a parasite infection, trauma, radiation therapy, tumors or inflammatory processes.<sup>82, 83</sup> However, very recent data suggests that secondary lymphedema is not exclusively due to environmental insult but can be linked to a heritable factors according to a model of genetic susceptibility<sup>84</sup>; a single heterozygous mutation of the gene, *GJC2*<sup>84</sup> has been found to promote lymphedema in some women undergoing medical treatment and surgery for breast cancer and, in one case, a familial *GJC2* mutation was associated to two sisters treated for breast cancer-related lymphedema.

### **Perspective on Edema (venous versus and lymphatic)**

The antiquated view that venous capillaries are normally in a state of sustained absorption is still widely taught as an established fact. This view has now been disproved by a) measurement of all four Starling forces in the same tissue, b) direct measurement of fluid exchange at venous capillary pressures and c) experimental and theoretical proof that extravascular colloid osmotic pressure is inversely related to filtration rate.

Therefore in the steady state the blood capillary produces a constant but dwindling fluid filtration with no reabsorption. This means that the lymphatic system is responsible for draining all microvascular fluid filtered except for periods of transient reabsorption lasting no more than a few minutes after which the blood capillary reverts to a state of filtration.<sup>22, 23</sup>

This means that lymphatic failure is responsible for all forms of peripheral edema, the mechanisms for which are a) only lymphatic failure (in the face of normal microvascular filtration) ie lymphedemalymphedema, b) a failure of lymph drainage to compensate for high microvascular filtration (increased capillary pressure, reduced plasma colloid oncotic pressure (COP) or increased microvascular permeability from inflammation) or c) lymphatic failure resulting from sustained increased microvascular filtration exhausting (so lymphedemalymphedema dissolves when high microvascular fluid filtration is corrected) and/or permanently damaging lymph drainage capacity (so lymphedemalymphedema remains even when high microvascular fluid filtration is corrected).

Therefore in circumstances of venous disease where corrective venous surgery is undertaken, eg EVT (endovascular therapy), but edema fails to resolve then lymphedemalymphedema is the explanation. The message to phlebologists is always to consider lymphatic failure in any clinical circumstance where edema exists.<sup>85</sup>

## **IV. Diagnosis - General Consideration**

### **General Guideline**

As a part of the diagnostic procedure, systemic causes of edema (e.g. heart failure, hypoproteinaemia, pulmonary hypertension, hypothyroidism, cyclic edema) should be excluded. In addition to a complete history and physical examination, some tests should be ordered especially for the "tarda" subgroup of patients; for them, lymphedema is diagnosis of exclusion and lymphoscintigraphy alone is insufficient to make a full diagnosis.<sup>87-90</sup>

Duplex ultrasonography should be included with scintigraphy in all forms of lymphedema including congenital, for differentiation from edema of mixed etiology.<sup>91, 92</sup> In some genetic forms of primary lymphedema such as Milroy disease and lymphedemalymphedema distichiasis syndrome, venous valve failure (venous reflux) frequently co-exists indicating the close relationship between venous and lymphatic development.<sup>86</sup>

Nevertheless, there is a danger of identify-

ing an 'incidental' venous pathology with the assumption that the venous abnormality is the cause of chronic edema and thereby neglecting the lymphatic component. Vein surgery in edema can have significant negative effects if the state of the lymphatics is not known. Therefore, both, venous and lymphatic systems should always be evaluated together when investigating chronic oedema.

Proper diagnosis should allow appropriate clinical and laboratory staging<sup>93</sup> of the disease for the assessment of progress of the condition and its response to treatment. Diagnosis should include a proper assessment of clinical and sub-clinical infections in the early and latent stages; such evaluation should be repeated aggressively not only for timely treatment but also for effective prevention of various conditions such as tinea pedis.

Diagnostic evaluation should include appropriate assessment of patient compliance since the outcome of successful management is totally dependent on this crucial factor.

Lymphedema among children is chiefly of primary origin. Their lymphedema can be part of a syndrome if there are other concomitant phenotypic abnormalities and if a genetic defect is recognizable. However, recognition relies upon careful personal and family history and physical examination in the initial phases.

Clinical evaluation will not be complete without documentation for lymphedema stage<sup>4-7, 93-95</sup> Stage 0 through Stage III, classification of severity of edema (volume): Mild – Moderate – Severe, proper description on the skin and subcutaneous tissue changes, and functional assessment of limb affected by lymphedema. WHO guidelines for International Classification of Functioning, Disability and Health and Quality of Life issues can be used as a reference on this complex condition of social, emotional, physical disabilities.<sup>96-98</sup>

## **Clinical Evaluation**

Evaluation of patients with presumed primary lymphedema must include a detailed history and clinical evaluation along with a thorough physical examination.<sup>91-93</sup> History should include age at onset, travel to tropical countries and history of all causes that could result in secondary

lymphedema including the medications with edema-causing potential (e.g. antipsychotics, anti-parkinsonian, cyto-coxics, bisphosphonates). History of temporary edema of the affected limb or other areas must be noted and a detailed family history of limb swelling should also be recorded.

Signs and symptoms of primary lymphedema should be documented. These include non-pitting edema, skin changes such as "peau d'orange, pinkish-red skin discoloration, hyperkeratosis, dermatitis, eczema, ulceration, varicosity, lymph vesicles, drainage of fluid, clear or milky, or yellow discoloration or other abnormalities of the nails. The presence of Stemmer sign<sup>99</sup> (skin fold of toes or fingers can barely be lifted), squaring of the toes, or puffiness of the forefoot (buffalo hump) should be noted.

The presence of venous, arteriovenous, or capillary malformations, or any tissue overgrowth eg increased/decreased leg length<sup>100, 101</sup>, increase in fat or muscle bulk should be recorded. Finally, any complications, such as cellulitis, lymphangitis, malnutrition, immunodeficiency or, rarely, suspicion for malignancies (lymphangiosarcoma) must be documented.

## **Diagnostic Tests - General Principle**

Basic initial diagnostic procedures for primary lymphedema should mimic those for early-stage secondary lymphedema (e.g. routine volumetry, symptoms of the patients ) to establish an early diagnosis in 'at-risk' patients .

An appropriate combination of non- to minimally-invasive tests typically should be able to provide all the information necessary to insure an adequate diagnosis and lead to the correct multidisciplinary, specifically targeted and sequenced treatment strategy. The tests and the information they can provide are indicated below.

### Non-invasive evaluations

Basic/Essential tests:<sup>67, 106-110</sup>

- Plain X ray
- Duplex ultrasonography<sup>86, 92, 102</sup>
- MRI with/without contrast<sup>103-105</sup>
- CT scan<sup>106, 107</sup>
- Radionuclide Lymphoscintigraphy<sup>108-110</sup>

Optional tests:

- Ultrasonographic lymphangiography<sup>11</sup>: in-

vestigational for the reconstructive surgery candidate patient

— MR lymphangiography<sup>111, 112</sup>: investigational for the reconstructive surgery candidate patient

— Microscopic fluorescent lymphangiography<sup>113, 114</sup>: investigational for the phlebolymphe-  
dema

— Indocyanine green imaging<sup>115, 116</sup>

— Indirect lymphography<sup>117</sup> using water soluble contrast agents

— Whole body blood pool scintigraphy (WBB-PS)<sup>118</sup>

— Volumetry<sup>119</sup>

— Bio-impedance Spectroscopy<sup>120</sup>

— Air plethysmography<sup>121</sup>

### 1. Plain x-rays

X-rays of bones will identify limb length discrepancies, bone abnormalities, or phleboliths in patients with combined LMs and VMs. Bone scanogram is specifically designed for the assessment of bone length.

### 2. Duplex ultrasonography (DUS)

DUS should include evaluation of the deep and superficial and local vasculature and the supra-fascial structures. Venous duplex studies should confirm any associated venous anomalies (valvular incompetence, obstruction, ectasia or aneurysms) and/or exclude venous obstruction as etiology or contributing factor to lymphedema.

The ultrasound evaluation of subcutaneous tissue thickness is a useful parameter to evaluate lymphedema and its response to treatment.

The suprafascial and the subfascial thickness of the edematous tissue is demonstrable through high resolution echography (and/or CT scan) and tissue compressibility<sup>122, 123</sup>. These are useful measurements that allow periodic assessment of the response to therapy and are useful in monitoring a patient's progress and determining prognosis.

In patients with lymphedema, thickening of the cutaneous, epifascial, and subfascial compartments has been ultrasonographically observed. This contrasts with MRI observations, where the subfascial compartment was shown to be unaffected.<sup>20</sup> High frequency ultrasound (20 MHz) reveals characteristic patterns of cutane-

ous fluid localization in various types of edema.

In lymphedema, there is a distinctively uniform pattern of distribution. This imaging technique has applications both in differential diagnosis and in therapeutic monitoring, although further refinement may become necessary to better characterize the spectrum of subcutaneous fibrosis that can be encountered in lymphedematous skin.<sup>124, 125</sup>

### 3. MRI and CT

MRI with or without contrast is indicated for further detailed evaluation of tissue overgrowth, pelvic pathology obstructing lymph drainage or malformations among the patients with a combined form of vascular malformations (e.g. Klippel-Trenaunay Syndrome).<sup>53, 54</sup>

In lymphedema, the images reveal a characteristic distribution of edema within the epifascial compartment, disclosing a honeycomb pattern along with thickening of the skin. In venous edema, both the epi- and subfascial compartments are affected, while in lipedema, there is fat accumulation without fluid.<sup>126, 127</sup>

Magnetic resonance imaging is also helpful in the identification of lymph nodes, enlarged lymphatic trunks, and in the differentiation of the various causes of lymphatic obstruction in secondary lymphedema. The anatomic information derived from MRI may complement the functional assessment provided by lymphoscintigraphy. At times, these complementary sources of information are necessary to establish the diagnosis and to make the requisite therapeutic decisions.<sup>103</sup>

### 4. Radionuclide Lymphoscintigraphy (LSG) (Table III)<sup>128-131</sup>

Scintigraphy is a functional study that complements the anatomical information provided by lymphangiography. There are no standardizations nor is there a gold standard as yet.

LSG, performed with injection of 99mTc-labeled human serum albumin or 99mTc-labeled Sulphur Colloid subcutaneously into the first and second web-space of the toes or fingers, is the test of choice to confirm or exclude lymphedema as the cause of chronic limb swelling.

Movement of the colloid from the injection site, transition time to the knee, groins or axilla, absence or presence of major lymphatic collec-

TABLE III.—Guidelines 6.2.0 of the American Venous Forum on lymphoscintigraphy and lymphangiography.

No.	Guideline	Grade of recommendation	Grade of evidence
6.2.1	We recommend lymphoscintigraphy for the initial evaluation of patients with lymphedema	1	B
6.2.2	We suggest lymphoscintigraphy, using visual interpretation of the images with a semiquantitative scoring index, to document response to treatment of lymphedema	2	B

1: we recommend; 2: we suggest; A) high quality; B) moderate quality; C) low or very low quality.  
Adopted from <sup>131</sup>.

tors, number and size of vessels and nodes (e.g. popliteal nodes), the presence of collaterals and reflux, symmetric activity with the opposite side are recorded and used for interpretation. <sup>132</sup> Semiquantitative assessment has been reported, and most recently, the technique of quantitative assessment of transit time from the foot to the knee was also validated <sup>(101-105)</sup>.

LSG remains the gold standard for lymphatic function evaluation since the LSG is the only test that can clearly indicate lymphatic function. Radionuclide lymphoscintigraphic findings provide the proper clinical and/or laboratory staging that may be essential for proper clinical management.

LSG, along with clinical evaluation, is the most essential component for the diagnosis of primary lymphedema. LSG is extremely useful for identifying the specific lymphatic abnormality and has largely replaced conventional oil contrast lymphography for visualizing the lymphatic network. LSG can easily be repeated with minimal risk. Data and images obtained from the study identify lymphatic (dys)function, based on visualization of lymphatics, lymph nodes, and dermal backflow as well as semi-quantitative data on radiotracer (lymph) transport.

However, the LSG has not been standardized with regard to the various radiotracers and radioactivity doses, different injection volumes, intracutaneous *versus* subcutaneous injection site, epi- or sub-fascial injection, number of injections, different protocols of passive and active

physical activity, varying imaging times, static and/or dynamic techniques. <sup>133</sup>

## 5. Newly developed Tests - Indocyanine green lymphography

Fluorescent lymphography using Indocyanine green <sup>134, 135</sup> has recently been shown to be a relatively easy and non-invasive means of assessing superficial lymphatic function in secondary lymphedemas. This water soluble compound has been used in assessment of hepatic function, for ophthalmic angiography and other clinical indications for over 50 years. Not only can it help in information provision regarding lymphovenous shunts but also as a diagnostic tool in the assessment of lymphatic function generally.

Patterns and signs in primary lymphedemas have yet to be elucidated but its simplicity, non-invasive and non-radioactive nature mean it presents an alternative to traditional lymphoscintigraphy, at least for superficial lymphatic functional assessment.

### *Invasive evaluations*

'Invasive' tests are seldom needed for the actual diagnosis but are occasionally needed for differential diagnosis; Further studies with invasive tests such as direct puncture percutaneous lymphangiography can be generally deferred to later stages if there is need for refining the diagnosis or if surgical or other invasive therapeutic measures are considered. Otherwise, these should be reserved for road-mapping in subsequent therapy if needed.

On some occasions an invasive study is required to provide more information for an accurate differential diagnosis. These tests and the information they provide are indicated below;

- Direct puncture percutaneous lymphangiography
- Standard (ascending) lymphangiography, optional for reconstructive surgery candidate patients, where indicated
- Fine needle aspiration biopsy of lymph node
- Skin biopsy in cases of suspected sarcoma, skin cancer or differential diagnosis of warty lesions.

Conventional oil contrast lymphangiography, especially if coupled with CT scan, is still advantageously employed in selected patients with chylous dysplasia and gravitational reflux disorders in order to define more clearly the extension of the pathologic alterations and sites of lymphatic and chylous leakage. These are the only diagnostic investigations that can clearly demonstrate pathologies of chylous vessels, chylous cyst and thoracic duct in cases of chylothorax, chylous ascites, protein losing enteropathy, etc.<sup>136, 137</sup>

### **Clinical and Laboratory Staging**

There have been substantial efforts over several decades to provide proper clinical staging of the lymphedema in conjunction with proper classification. There are many different staging systems<sup>93-95</sup>, including a three staging system (Stage 1 through 3) proposed by the International Society of Lymphology (ISL); more recently, Stage 0 has been added to this schema.

Most of the currently available staging systems reflect only tissue turgor and limb shape, etc and neglect other critical clinical information (e.g. number of major joints with changes in tissue composition) as well as socioeconomic status to reflect quality-of-life (QoL) properly.<sup>93-98</sup>

Therefore, many new proposals were made to compensate for such discrepancies; these include the Lymph CEAP classification by Europeans and U.S.-based combined staging of two separate Clinical and Laboratory staging based on the lymphoscintigraphic findings.<sup>93-95, 138</sup> But none of the current staging systems are able to meet the mandate as contemporary guidelines for improved management of lymphedema in different stages.

## **V. Treatment - General Consideration**

### **General Guideline**

Patient involvement in management is essential, especially for home maintenance. Patients should be encouraged to be aware of the nature of the disease and should be properly guided on how to be actively involved actively in self-management.

The treatment of children with lymphedema must be chiefly conservative, utilizing DLT in-

cluding compression therapy, directed exercises, massage and skin care. In the neonate, initial observation alone may be sufficient, as delayed lymphatic development and maturation can result in spontaneous improvement. The role of parents is crucial in providing the necessary input.

Proper management of various co-morbid conditions such as congestive heart failure, obesity, sleep apnoea, granulomatous disease, neurological disability and chronic arthritis is essential for the safe management of lymphedema since these co-morbid conditions will influence the therapeutic approach taken. Also calcium-channel blocking agents should be avoided as they impair lymphatic pumping.<sup>139</sup> Medications that stimulate sodium retention, such as NSAIDs, should be similarly avoided.

The ultimate goal of treatment is to improve the physical characteristics of the affected limb or area as well as the QoL,<sup>96-98, 140</sup> thus achieving,

- Better social adaptation and a socially useful life,
- Better functional adaptation with physically normal activity, and
- Better psychological adaptation despite a psychologically unacceptable physical deformity.

Contemporary management of chronic lymphedema is now based on Decongestive Lymphatic Therapy (DLT).<sup>141-145</sup>

## **VI. Treatment - Physical & Pharmacological Therapy**

Decongestive Lymphatic Therapy (DLT) based on compression therapy-

DLT is now well established as the treatment of choice for lymphedema regardless of the underlying etiology (primary or secondary) or its clinical stage. DLT consists of compression (bandaging, garments, intermittent pneumatic compression) therapy, movement exercises, manual lymphatic drainage (MLD), in addition to basic skin care, and education for risk reduction. Appropriate management of subjective symptoms and psychosocial management should also be included in the treatment regimen.

Compression bandage-based DLT with or without sequential intermittent pneumatic com-

pression (SIPC)-based mechanical compression therapy<sup>146-149</sup>, is the single most important component of DLT.

In the initial management phase of lymphedema, short-stretch bandaging should be adopted, together with exercises and meticulous skin care, guided by specifically trained staff. The type and level of the bandaging and garments are still under evaluation.<sup>150</sup> This is an empirical strategy to control the edema and does not result in a "cure".

The maintenance phase after initial decongestion should be based on a practical combination of compression garments (e.g. tailored round or flat knitted garments depending on the stage and extent of the lymphedema), self management (e.g. compression bandage or velcro-devices and/or self massage), skin care and exercises to continue to reduce lymph formation, promote uptake of fluid and their contents from the interstitium and maintain lymph transport. This phase requires life-long commitment.<sup>150</sup>

However, the specific mechanism of action and the optimal dosing of compression requires more research. Less bulky bandages and velcro-band devices, rather than the widely used multilayer-multicomponent bandages, allow better movement and show superior outcomes.<sup>151, 152</sup> Recent experimental data support the view that there is an optimal pressure range for reducing edema, corresponding to a pressure range around 30 mm Hg for the upper and 50-60 mm Hg for the lower extremities.<sup>153</sup> Higher pressures may be counterproductive. The main goal is to prevent edema and fibrosis. If this can be reached by lower compression pressure individually, then lower compression is appropriate and may help to improve compliance.

These findings from studies in postmastectomy arm lymphedema<sup>154</sup> and in patients with chronic venous edema in the lower extremities<sup>155</sup> excluding extreme fibrotic and elephantiasis indurations need to be confirmed by further investigations comparing the dose (pressure) with more outcome parameters than just volume reduction.<sup>150</sup> Due to the pressure drop of inelastic material this concept of an optimal pressure range has important implications concerning the timing of bandage changes. Bandages changed in daily intervals should not be applied with the same high pressure compared to bandages changed once or twice weekly.

In a recent study it was shown that self-adjustable velcro-band devices, applied by lymphedema patients themselves may reduce edema even more effectively than inelastic lymph bandages.<sup>152</sup> This may be explained by the fact that the patients avoided unacceptably low and high pressures during self-application and self-readjustment.

MLD has not been fully scientifically documented and remains to be confirmed with objective data.<sup>156, 157, 158</sup>

However, MLD has become an indispensable treatment modality. The MLD component of DLT is believed to reduce lymphatic congestion effectively by physiologic stimulation of a poorly functioning lymph-transporting system thereby encouraging interstitial fluid entry into the initial lymphatics. In addition to improving lymphodynamics during treatment sessions and immediately after, it may also reduce the fibrosclerosis of the involved soft tissues, although this effect is conjectured but not established.<sup>159-161</sup>

DLT can be applied with minimal risk of complication and morbidity and can improve disease status in the majority of patients, regardless of the underlying etiology. It is more effective when started in the earlier (fluid) stages of lymphedema, and when utilized in the compliant, motivated patient who is committed to life-long therapy. In the later stages of lymphedema, the efficacy of DLT is very much limited to the maintenance of the current stage of lymphedema at best and, possibly, prevention of progression and of complications. DLT is therefore, not curative but may stabilize disease or even prevent progression, and it produces a satisfactory outcome in the majority of cases. This is especially true when the patient is compliant and maintains a self-motivated home treatment schedule with a life-time commitment.

DLT is often the only effective treatment in 'advanced' lymphedema.

SIPC can be used as an adjunct treatment modality and using a mechanical pumping device, is particularly useful in those cases where lymphedema is treated by passive physical therapy (e.g. elderly, patients in bed, with serious disabilities, etc.) in whom spontaneous/isotonic physical exercise is highly compromised or absent, and to maintain results (home self-therapy). Optimal settings concerning pressures, pattern and tim-

ing sequences of the pressure in such pumps need further clarification.<sup>162, 163</sup>

Proper occupational therapy can augment the selected muscle exercises, often forgotten by the patients in most important clinical stages.<sup>97, 98.</sup> Psychological support is also extremely important in the lymphedema patient and is helpful for maintenance of compliance, especially for children and family members.

There are, however, a few theoretical, relative contraindications to each component of the DLT: MLD with the risk of intravascular cancer metastases/thrombosis during the manipulation; and high pressure bandaging to the patient with advanced cardiac failure; and in advanced peripheral arterial disease of the limb (Table IV).

### **Pharmacological Treatment**

Pharmacological trials of oral pharmaceutical treatments encompassing coumarin and derivatives, hydroethylrutosides, calcium dobesilate, escin extracts, 0-(beta-hydroxyethyl)-rutosides and MPFF found that such drugs may help lymphedema treatment by reducing protein and extracellular fluid accumulation<sup>165</sup>, stimulating lymph contractility and flow<sup>166</sup>, and reducing protein concentration and fibrotic induration in tissues by stimulating proteolysis.<sup>167, 168</sup>

However, the investigation on the effect of oral pharmaceuticals based on three clinical trials with coumarin have shown conflicting results.<sup>168-170</sup>

The first study investigating two dosages, 90 mg (n = 23) and 135 mg (n = 30) over 12 months showed at the end that both groups experienced similar reduction in percentage of the limb.<sup>169</sup> The second study used a cross over design to compare the 6-month phase of coumarin (400 mg) to the 6 month phase of a placebo (n = 138).<sup>170</sup> Results demonstrated edema worsening in both treatment and placebo phases. The third study used the same cross over design as above and results demonstrated that the amount of edema of the legs was reduced from 25 percent to 17 percent above normal and that nearly one third of the edema fluid was removed from the legs. During the six months of the placebo period, the amount of edema of the legs was unchanged from 24 percent above normal.<sup>168</sup>

The 0-(beta-hydroxyethyl)-rutosides were

TABLE IV.—Guidelines 6.3.0 of the American Venous Forum on lymphedema: medical and physical therapy.

No.	Guideline	Grade of recommendation	Grade of evidence
6.3.1	To reduce lymphedema we recommend multimodal complex decongestive therapy that includes manual lymphatic drainage; multilayer short-stretch bandaging; remedial exercise; skin care; and instruction in long-term management	1	B
6.3.3	To reduce lymphedema we recommended treatment daily, a minimum of 5 days per week, and continue until normal anatomy or a volumetric plateau is established	1	B
6.3.4	To reduce lymphedema we suggest compression pumps in some patients	2	C
6.3.5	For maintenance of lymphedema we recommended an appropriately fitting compression garment	1	B
6.3.6	For maintenance of lymphedema in patients with advanced (stages II or III) disease we recommend using short-stretch bandages during the night. Alternatively, compression devices may substitute for short-stretch bandages	1	B
6.3.7	For remedial exercises we recommend wearing compression garments or bandages	1	C
6.3.8	For cellulitis or lymphangitis we recommend antibiotics with superior coverage of Gram-positive cocci, particularly streptococci. Examples include cephalixin, penicillin, clindamycin, cefadroxil	1	A
6.3.9	For prophylaxis of cellulitis in patients with more than three episodes of infection we recommend antibiotics with superior coverage of Gram-positive cocci, particularly streptococci, at full strength for 1 week per month. Examples include cephalixin, penicillin, clindamycin, cefadroxil	1	C

1: we recommend; 2: we suggest; A) high quality; B) moderate quality; C) low or very low quality.  
Adopted from<sup>164</sup>.

studied in 6 months randomized, double-blind, cross-over trial performed on 26 patients with postmastectomy lymphedema of the arm, and 14 with lymphedema of the leg. The active drug significantly reduced the volume and circumference of the limbs. Patients reported increased comfort and freedom of movement, a reduction of their bursting pains, heaviness and tension, and an increased mobility of their limbs.<sup>171</sup>

From the 15 selected trials of the effect of pharmacological treatment in the reduction of limb lymphedema, the authors of the last Cochrane review were not able to perform a meta-analysis due to the heterogeneity of study designs. Consequently they did not draw conclusions about the effectiveness of these drugs in reducing limb volume, pain, or discomfort in lymphedematous-lymphedematous limbs.<sup>172</sup>

Despite the use of benzopyrone remaining an unsettled issue in view of its hepatic toxicity and it is currently not approved for clinical use in the U.S. or in the U.K., a combined approach<sup>173</sup> implementing conventional physical therapy, medical treatment using benzopyrones<sup>174</sup>, and various physical<sup>175</sup> and surgical treatments remains the favored approach.

However the literature<sup>176</sup> indicates that better use of pharmacogenomic knowledge (screening patients for genetic polymorphisms) could significantly reduce the risk of benzopyrone associated hepatotoxicity by limiting the use of benzopyrones (particularly coumarin) to those with a functional non-polymorphic CYP2A6, a liver enzyme responsible for the metabolism of coumarin to non cytotoxic metabolites rather than o hydroxy-phenylacetaldehyde, which is cytotoxic.

## VII. Treatment - Surgical/Operative Therapy

### General Overview

There are four different surgical approaches to the treatment of primary lymphedema.. Each surgical approach has distinctively different indications for the various stages of primary lymphedema.

— Reconstructive surgery with various microsurgical lympho-venous anastomoses<sup>177-180</sup>: this is best utilized in the early stages of lymphedema prior to the development and progression to

the fatty fibrous stages where lymph vessels may show signs of fibrotic (functional) changes - clinical stage I & II (early stage)

— Reconstructive surgery with autologous free lymph nodes transplant surgery<sup>177, 180</sup>: is best utilized in patients with lymphadenodysplasia - clinical stage II & III. It remains a controversial procedure whose efficacy has not yet been fully established.

— Debulking/Ablative (excisional) surgery<sup>12, 181-184</sup>: is best utilized when there are massive limb changes and when there is significant fibrotic induration. It is the least preferred approach of all of the surgical strategies - clinical stage III & IV (end stage)

— Circumferential suction-assisted lipectomy<sup>122, 123, 185, 186</sup>: is a lipo-remediation techniques to remove adipose tissue when the patient is in the adipo-fibrous (mid) stage and DLT and MLD etc., have failed - clinical stage II & III. This procedure has been reported to be effective in secondary lymphedema, but its utility in primary lymphedema with regard to its timing and to potential risks in truncular lymphatic malformation (LM) is not established<sup>187, 188</sup> Its safety has not been proven, especially in cases of co-existing when extratruncular LM<sup>189, 190</sup>.

These surgical interventions require specialized techniques and experience as well as specific followup to achieve optimal outcomes. Those wishing to utilise these techniques should receive specific training with the relevant expert groups.

Lymphatic-venous anastomosis for reconstruction<sup>191-194</sup> involves various technical aspects including the interposition of an autologous vein graft between lymphatics above and below the lymphatic obstruction. This technique is used in those cases involving the lower limbs, where surgically non-correctable disease exists (interpositioned vein grafted shunt or lymphatic-venous-lymphatic anastomosis - LVLA).<sup>192</sup>

### Dilemma and Controversy

The first indication for additional surgical therapy is a well-documented, steady progression of the disease, despite maximum of MLD-based DLT for a minimum a six month to two year period.<sup>195, 196</sup> However, two years of maximum therapy is generally considered to be too long and

conservative before being declared a “treatment failure.” Due to medicolegal and medicoethical issues involved in the treatment of primary lymphedema, while DLT remains first line treatment, two years is the generally accepted time period for the confirmation of a failed treatment by the IRB (Institutional Review Board).

There remains significant controversy regarding this waiting period before considering reconstructive surgery. A delay of surgery for more than one year will increase the risk of surgical failure due to chronic lymphatic damage. Therefore, this waiting period should be shortened as much as possible, especially in compliant patients who stand to benefit the most from lymphatic reconstruction.

Surgical therapy for primary lymphedema should remain a treatment option as supplemental therapy in patients who have a non- to poor-response to DLT and/or compression therapy. This is especially true in the U.S. where rigid criteria for treatment indications are influenced by medical-legal-ethical conflicts. Within the good response group of patients in whom lymphedema relapses after DLT, notwithstanding the use of elastic garments, there are patients who can be excellent surgical candidates with outcomes similar to those in the early stage, treatment failure/non-responding group.

Patient compliance with life-long DLT therapy following surgical treatment is the single most important factor in ensuring successful surgical management of lymphedema unless microsurgery is applied early enough as a preventive approach.<sup>197, 198</sup> In addition, the prevention and treatment of systemic and local infection such as cellulitis and erysipelas is equally important to prevent further injury to already jeopardized lymph vessels following successful reconstructive surgery.<sup>199</sup> There is also a research indicating that the lymph stasis is a cause of poor immune response, and therefore increased risk of infection. This implies that improving the lymph flow with surgery decreases risk of infection.<sup>200</sup>

The role of reconstructive surgery in early stage lymphedema and excisional surgery in late stage lymphedema remains a decision for the multidisciplinary management team. Full integration with DLT-based therapy can deliver effective control of the condition in both in early and late stage lymphedema. Life-long compli-

ance and follow up is necessary for successfully treatment including postoperative DLT and compression garments.

## **Reconstructive Surgery - Lymphatic Microsurgery**

### **1. General Principles**

Reconstructive surgery to restore lymphatic function with newly created lympho-venous or lympho-lymphatic bypass, lympho-lymphatic venous segmental reconstruction, or free lymph node transplantation of a damaged lymph-transport system to enhance lymph flow is more theoretically sound than DLT, with a definite chance of ‘cure’ in early stage lymphedema.

The LM as the cause of primary lymphedema accompanies an extremely variable number of lymph vessels and lymph nodes by the various forms of dysplasias such as lymphangio-dysplasia, lymphadeno-dysplasia, and lymphangio-adeno-dysplasia (Papendieck’s classification), and variations among the lymph nodes and lymph-transporting system (e.g. aplasia, hypoplasia and hyperplasia).<sup>34, 201</sup>

Therefore, proper candidates for reconstruction are much more rare among the primary lymphedemas due to such variation within the lymph nodes and lymph-transporting system (e.g. aplasia, hypoplasia and hyperplasia).<sup>193, 194</sup>

Nevertheless, excellent results have been reported even in primary lymphedema, with claims that there are many candidates with suitable lymph vessels for the reconstruction with the condition of lymphadeno-dysplasia than lymphangio-dysplasia.<sup>193, 194</sup>

Reconstructive surgery outcomes are also known to be much more variable and generally not as effective as those seen when performed to treat secondary lymphedema, where a surgically correctable lesion is often found along the major lymphatics and collectors. Excellent results have been reported even among the primary lymphedema, with claims that there are many candidates with suitable lymph vessels for reconstruction with a prevailing condition of lymphadenodysplasia rather than lymphangiodyplasia.<sup>34, 201</sup> However, many others failed to confirm these same observations and this issue remains to be supported with further evidence.

Lymphatic surgical reconstruction is known to be technically demanding, requiring microsurgical techniques that are often available only at specialized centers where lympho-venous procedures are routinely performed. These demands have hampered the widespread proliferation and acceptance of lymphatic reconstruction as the first-line treatment of lymphedema. This is especially true in the primary lymphedemas, despite the theoretical potential for disease reversal. Only a handful of institutions throughout the world continue to devote the effort and resources required to maintain an active lymphatic surgical reconstruction center. Access to these techniques is extremely limited.

## 2. Candidate Selection & Indication

Early stage lymphedema should be considered as an ideal candidate for reconstructive surgery, since there is a significant risk of from progression of disease to fibrotic changes in the lymphedema patient. There remains significant controversy regarding a suitable waiting period before considering reconstructive surgery.

A delay of surgery for more than one year will increase the risk of surgical failure due to chronic lymphatic damage. Moreover, functional magnetic resonance imaging demonstrates improvement of cortical alterations in patients after early microsurgical treatment of reversible congenital lymphedema.<sup>202</sup>

Therefore, the timing of lymphatic reconstruction remains most crucial and this waiting period should be shortened as much as possible. Thus, indications for lymphatic reconstructive surgery may be summarized as follows: failure to respond to proper therapy at clinical stage I or II; progression of the disease to advanced stages, despite proper treatment; chylous-reflux combined with extremity lymphedema; multiple recurrences of local or systemic infection; poor tolerance- *physically, mentally and socioeconomically*- of DLT-based conservative treatment.

A policy for lymphatic reconstruction that limits the candidates to those who fail DLT-based therapy will result in further damage to the lymphatic system and, subsequently, a higher likelihood of procedure failure. Therefore the wider inclusion criteria above are preferred.

In fact, the majority of candidates for lymphat-

ic reconstruction have already had significant damage to lymph-transporting vessels caused by long-term lymphatic hypertension. Postoperative maintenance of DLT following successful reconstructive surgery is essential to maintain good long term outcomes. Without appropriate DLT assistance to partly damaged lymph vessels, even flawless technical surgical successes become futile.<sup>89, 90</sup>

A majority of patients have very poor compliance and do not maintain postoperative DLT that is required for the long term success of delayed surgery. Postoperative DLT totally depends upon patient compliance. Patient compliance is absolutely necessary for successful lymphatic surgery.<sup>89, 90</sup>

Due to the variety of such barriers, reconstructive lymphatic surgery has remained an adjunctive therapy. Yet in most cases, when optimally performed, it can result in effective treatment of primary lymphedema.

### Ablative Surgery - Excisional Surgery

Ablative (cytoreductive) surgery is based on excisional techniques to reduce fibrosclerotic overgrowth, while liposuction can obliterate the epifascial compartment by removal of overgrown adipose tissue.

Several operations<sup>182-104, 203-206</sup> to treat lymphedema have been introduced throughout the decades (e.g. Charles procedure<sup>204</sup>, Homan's procedure<sup>183</sup>), but have ultimately been abandoned by the majority of vascular surgeons due to the associated morbidity and poor long-term results. More recently however, modifications of the original techniques have resulted in significant improvements in morbidity with improved outcomes (e.g. Modified Auchincloss/Homan procedure) (Table V).<sup>203</sup>

Once the lymphedema advances to an irreversible stage, it has a tendency to progress steadily despite aggressive DLT with or without complementary compression therapy.

When the lymphedema progresses to its late end stages (stage III and IV of chronic lymphedema), the majority of patients will have an increased risk of recurrent local and systemic sepsis. In addition, due to the progressive deformity of the affected limbs, proper DLT becomes technically difficult. Therefore, once the multidisci-

TABLE V.—Guidelines 6.4.0 of the American Venous Forum on principles of surgical treatment of chronic lymphedema.

No.	Guideline	Grade of recommendation	Grade of evidence
6.4.1	All intervention for chronic lymphedema should be preceded by at least 6 months of non-operative compression treatment	1	C
6.4.2	We suggest excisional operations or liposuction only to patients with late stage non-pitting lymphedema, who fail conservative measures	2	C
6.4.3	We suggest microsurgical lymphatic reconstructions in centers of excellence for selected patients with secondary lymphedema, if performed early in the course of the disease		

1: we recommend; 2: we suggest; A) high quality; B) moderate quality; C) low or very low quality. Adopted from <sup>206</sup>.

plinary team admits its failure to arrest lymphedema progression toward the end stages with DLT and with evidence of steady deterioration despite maximum treatment, excisional surgery can be offered as a supplemental measure of last resort to improve the efficacy of available DLT.<sup>11, 12</sup>

Evaluation of potential candidates for palliative excisional surgery should be performed when the clinical stage of chronic lymphedema reaches the end-stages of lymphedema (stage IV or late stage III) and accompanied by;

- increased difficulty in providing effective DLT due to a highly disfigured limb and/or failure to be able to wrap adequately with a bandage for exercise therapy.

- increased frequency and severity of local and systemic sepsis.

Indications for ablative surgery include;

- 1) failure to implement proper care at clinical stage III or IV (end stage)
- 2) progression of the disease to end stages in spite of maximum available treatment
- 3) increased frequency and/or severity of local and/or systemic sepsis.<sup>19, 20</sup>

However, compliance with maintenance DLT postoperatively becomes a major critical issue

for long term success of excisional surgery. Without adequate postoperative DLT; excisional surgery alone cannot maintain the initial excellence of the surgical achievements and is highly likely to fail in the long term.<sup>12</sup>

### **Ablative Surgery - Circumferential suction-assisted lipectomy**

The current application of liposuction is a selective removal of excessive adipose tissue alone, when this complicates secondary lymphedema of the upper limb following breast cancer treatment, or in other secondary causes of limb lymphedema.<sup>185, 186</sup>

Therefore, the patient most likely to benefit from this procedure is one who has a unique condition of an excess fat accumulation as a manifestation of the lymphedema, although control of the hydrostatic component of lymphedema is mandated continuously with conventional bandage-based and /or stocking- based compression armsleeve therapy before and after the liposuction.

For primary lymphedema, which has an entirely different pathogenesis as a truncular LM, the efficacy of liposuction has not been proven. After all, the target for the suction ablation of swollen arm is the adipose tissue and NOT the lymphedematous tissue. However, it has been claimed there is no risk of additional damage by the liposuction to the remaining lymphatic system.<sup>185, 186</sup>

The clinical course of primary lymphedema, mostly affecting the lower extremity as a truncular LM, is not same as that of secondary lymphedema affecting of the extremity; there is no clear evidence of selective overgrowth of the adipose tissue among this group. When the condition of ‘pitting’ edema progresses to ‘non-pitting’, the whole tissue becomes fibrosclerotic with very limited amount of fat tissue available for liposuction to improve local swelling.

Therefore, liposuction cannot be utilized in end stage primary lymphedema as a replacement for the currently employed excisional surgery.

Furthermore, primary lymphedema as a clinical manifestation of truncular LM is associated with significant risk for combined extratruncular LM. When coexisting extratruncular LM is stimulated by the liposuction, its mesenchymal

cell characteristics will cause it to grow rapidly and make the condition worse.<sup>149</sup>

## VIII. Special Issue: Elephantiasis

### General concept

Elephantiasis is a unique condition that characterizes the end stage of lymphatic impairment, with profound dermal as well as soft tissue changes. According to the International Society of Lymphology<sup>4</sup>, elephantiasis is classified as Stage III (in a Stage 0 to III clinical classification of lymphedema) where "...pitting can be absent and trophic skin changes such as acanthosis, further deposition of fat and fibrosis, and warty overgrowths have developed."

Elephantiasis reflects the most advanced clinical stage of lymphedema without regard to the underlying cause; while the presentation of tissue fibrosis, fat deposition and skin lesions may vary widely the clinical stage retains its designation due to the limb disfigurement.

All of these patients present a long history of limb swelling without proper treatment for many years and often complicated by secondary infection/cellulitis, slowly progressing to this debilitating and disfiguring chronic manifestation.

Lymph stasis may result in, among others, altered adipocyte metabolism and proliferation. Thus, localized adipose tissue enlargement could accompany primary lymphedema if remains untreated. If primary lymphedema is combined with morbid obesity, clinical symptoms could appear in a more advanced form therefore overweight status is considered as an important secondary trigger factor.<sup>207-210</sup>

The two most striking characteristics of this end-stage condition of lymphedema have been fully described by Moritz Kaposi<sup>211</sup> long before the etiopathogenic factors were known: the relationship between elephantiasis and recurrent inflammatory attacks and the tissue changes. Elephantiasis occurs "after a series of short-term paroxysmal inflammatory episodes ... (that) after five to ten years lead to hypertrophy of the skin and subcutaneous tissue".

The majority of elephantiasis is caused by infection, especially in the global health context of lymphatic filariasis. Primary lymphedema can

also progress to the condition of elephantiasis if untreated<sup>212</sup> and infection is allowed to supervene.

The clinical signs are the distinctive dermatological findings of severe epidermal and dermal changes, with dermal fibrosis, hyperkeratotic, verrucous, papillomatous, nodular lesions displaying a cobblestone-like appearance. Warty skin overgrowths are sources of bacterial and fungal colonization and skin abrasions and moist environment causes recurrent cellulitis/infections.

Lymphatic filariasis is still the most prevalent cause of secondary lymphedema worldwide and remains an endemic disease in more than 80 countries. About 1.39 billion people live in areas at risk.<sup>214</sup> The most common presentation of elephantiasis is in lower limb and/or genital involvement with the secondary lymphedema of filarial infection.

The current classification of elephantiasis is based on tropical<sup>208</sup> and non-tropical elephantiasis of secondary origin; the various conditions that cause non-tropical/nonfilarial elephantiasis are grouped separately as elephantiasis nostras verrucosa (ENV); Morbid obesity<sup>213</sup>, chronic venous insufficiency, recurrences of lower extremity cellulitis/lymphangitis and/or chronic soft-tissue infection are known to cause ENV. Alternative terms for this disorder include lymphostatic verrucosa, lymphostatic papillomatosis cutis, elephantiasis crurum papillaris et verrucosa and mossy foot and/or leg.

Among the other lymphatic disorders that produce elephantiasis is podoconiosis, a common but neglected tropical disease.<sup>215</sup>

Podoconiosis is a non-infectious geochemical elephantiasis caused by exposure of bare feet to irritant alkalic clay soils. It is found in at least 10 countries in tropical Africa, Central America and northwest India, where such soils coexist with high altitude, high seasonal rainfall and low income. Podoconiosis develops in men and women working barefoot on irritant soils, with signs becoming apparent in most patients by the third decade of life".<sup>216</sup> It is estimated that more than 4 million people are affected worldwide.<sup>215</sup>

### Management

Specific publications concerning management of elephantiasis in primary disorders of

the lymphatic system refer only to case reports. Larger series where late stage lymphedema are considered are difficult to interpret due to the wide range of clinical presentations found in this group of patients; sometimes authors employ classifications using volume excess while others will take into account the degree of fibrosis and skin changes and/or limb deformity.

Elephantiasis is the result of a long-lasting, untreated condition. Independent of its origin, elephantiasis can be prevented by early recognition of lymphedema for appropriate treatment with prevention of aggravating factors. Therefore, the treatment should focus on prevention of developing this condition. Simple measures like adequate hygiene of the skin is a cornerstone to elephantiasis prevention.<sup>217</sup> and early diagnosis is essential.

All patients with primary lymphedema must have proper skin care, which is the most useful conservative treatment available, together with physical treatment and compression. In patients with elephantiasis, of all the treatment modalities available, skin care is the most important, since infection is responsible for the progression of initial stages of lymphedema to elephantiasis.<sup>218</sup>

Aggressive treatment of skin lesions is mandatory to reduce disease progression. Warty skin overgrowths are sources of bacterial and fungal colonization and, if adequate care does not prevent skin abrasions and moist environment, they may also benefit from local surgical excision. In severe cases, aggressive treatment of skin lesions by surgical excision is mandatory followed by compression therapy to reduce disease progression.<sup>210</sup>

In addition, aggressive weight control is an essential step to prevent further aggravation of primary lymphedema to progress to its end stage.<sup>207</sup> Lifelong administration of antibiotics should be considered in primary elephantiasis as recommended for filarial patients,<sup>4</sup> at least until further scientific evidence contraindicates its use.<sup>219</sup>

Compression treatment can obtain significant volume reduction and partial regression of skin lesions. As compression therapy by custom-made garments is mandatory to maintain limb girth in long-term treatment, sometimes additional surgical procedures are required to resect

redundant skin and achieve a favorable limb shape in order to avoid ineffective compression therapy because of the irregular limb contour.<sup>212</sup> Many publications suggest good results after reduction surgery in genital elephantiasis.<sup>220-222</sup>

However, this resection surgery is accompanied by significant morbidity and complications, and postoperative compression therapy is mandated to maintain the initial surgical outcome.<sup>11, 12, 205</sup>

Patients with end-stage lymphedema and elephantiasis are not suitable candidates for lymphovenous bypasses since all the lymphatic vessels are already damaged by persistent lymphostasis beyond the level of functional recovery, with massive irreversible skin and tissue changes.<sup>193</sup> Circumferential suction-assisted lipectomy is effective to remove adipose tissue of lymphedematous arms and legs.<sup>223-225</sup> However, when the lymphedema reaches the stage of elephantiasis, with profound soft tissue and epidermal changes, this method is rendered much less useful, since most of the adipose tissue is replaced by fibrotic tissue through the protracted process of progressive dermatolipofibrosclerosis.

When elephantiasis is combined with hyperkeratotic lesions, some studies show efficacy of oral etretinate therapy<sup>226, 227</sup> in flattening the hyperkeratotic, verrucous and papillomatous lesions. Etretinate has more recently been replaced by acitretine, which has similar potency with less severe side effects.<sup>228</sup>

## IX. Special Issue: Phlebolympedema

### Definition

Phlebolympedema (PLE) represents a unique clinical condition of 'combined insufficiency' of both venous and lymphatic systems, ie, simultaneous chronic venous insufficiency (CVI) and chronic lymphatic insufficiency (CLI), with various causes.<sup>138, 229, 230</sup>

*Primary phlebolympedema* is mostly caused by 'congenital' malformation affecting the venous and lymphatic systems simultaneously; they are a combined condition of venous and lymphatic malformation (as the outcome of defective development during various stages of embryogenesis). The CLI of primary PLE is a dif-

fuse condition of lymphedema caused by a truncular LM<sup>92, 187</sup> from the outset in the majority of patients, together with the CVI caused by the VM.<sup>45, 231</sup>

This combined condition of VM and LM often represents one aspect of the clinical manifestation of Klippel-Trenaunay Syndrome (KTS)<sup>53, 232</sup> as its vascular malformation components. KTS is characterized by having both vascular malformation components as well as non-vascular anomaly of congenital origin affecting the soft tissues and skeletal system.<sup>233, 234</sup>

*Secondary phlebolymphe* is much more frequent than the primary form.

In contrast, the pathophysiology of secondary PLE is not as complicated as the primary condition; this 'acquired' condition begins with CVI due to various causes, often as a part of post-thrombotic syndrome following deep vein thrombosis (DVT).

Often this condition is the outcome of the advanced stages of CVI, complicated by non-healing venous stasis ulcer. It may also be frequently observed in morbid obesity.<sup>235, 236</sup> CVI results in lymphatic dysfunction leading to CLI as its culmination.<sup>237, 238</sup>

Hence, the CLI of secondary PLE is generally limited to a regional/local condition as a complication of CVI following chronic recurrent infection/inflammation and reactive fibrosis.<sup>239, 240</sup>

Microlymphangiopathy may be demonstrated in all these cases.<sup>114, 241, 242</sup>

Therefore, proper assessment of this 'dual' outflow system failure (CVI + CLI) warrants a correct understanding of the interrelationship between the venodynamics and lymphodynamics.

### **Pathophysiology-Hemodynamics**

Although the venodynamics and lymphodynamics are based on distinct hemodynamic mechanisms, the venous and lymphatic systems are a mutually dependent dual outflow system of the circulation. Therefore, they are one 'inseparable' system and the insufficiency or overload of one or both systems allows the other to play an auxiliary role to compensate in fluid return.<sup>243</sup>

However, both systems are 'mutually complementary' ONLY when they are functioning normally. When one of the two systems loses its normal function (e.g. chronic venous hypertension,

lymphedema), such mutual interdependence generates a new problem for the other. In other words, failure of one system gives an additional burden/load to the other system. Long term single system failure results in total failure of this 'inseparable' dual system, resulting in the unique clinical condition of PLE.

When CVI results in an excessive fluid load at the tissue level, it increases afterload on the capillary, creating additional load for the lymphatic system. When this overload exceeds the maximum capacity of normal lymphatic compensation, it results in CLI. CLI becomes more prominent especially in a compromised lymphatic drainage/transport system due lymphatic dysfunction of various etiologies of primary (e.g. hemolympathic malformation) and secondary origin (e.g. surgery and radiotherapy associated with cancer treatment).

In the Bonn Vein Study (Pannier 2007)<sup>244</sup> 8.1% of the C4 patients and 11.1 % of the C5 patients showed a significant positive Stemmer's sign of the toes indicating phlebolymphe

Nevertheless, 'primary' PLE is still a relatively under-recognized condition. It is the most common manifestation of the 'hemolympathic' malformation (HLM) consisting of a VM and LM, often as the clinical condition of the KTS. When an AVM<sup>245</sup> is further combined with VM and LM, known as Parkes-Weber Syndrome, primary PLE becomes much more difficult to manage.<sup>246, 247</sup>

### **Clinical Evaluation**

The basic evaluation of VM and LM as a cause of primary PLE should include a thorough history and physical examination; the combination of DUS, MRI/CT and LSG is generally sufficient to confirm the clinical diagnosis of combined VM and LM.<sup>55</sup>

Assessment of PLE should be extended to further assessment of the extent and severity of the CVI and CLI, since these will determine the variable clinical manifestations.

Simultaneous evaluation of both venous and lymphatic systems is mandated for all primary PLE cases. A variety of laboratory tests is available for assessment of venous and lymphatic system and these are sufficient to provide the necessary hemodynamic information for proper management.<sup>248</sup>

The assessment of the extent and severity of the CVI should begin with DUS and may include various plethysmographic studies in addition to ascending/descending phlebography, in order to identify the etiology (e.g. marginal vein).<sup>55</sup>

The most common VM to cause CVI leading to primary PLE is the 'lateral embryonic vein' represented by marginal vein (MV).<sup>249, 250</sup> This is one form of truncular VM lesion developed during the later stage of embryogenesis. MV causes severe venous reflux and venous hypertension due to the absence of venous valves as a part of defective development.<sup>251, 252</sup>

The second most common VM to cause the CVI is deep vein dysplasia (e.g. iliac vein agenesis, hypoplastic femoral vein) or defective vein (e.g. web, stenosis, vein valve agenesis, aneurysm, ectasia) with venous outflow obstruction and reflux to cause venous hypertension.<sup>253, 254</sup>

An extratruncular VM lesion as a VM component among KTS patients seldom causes CVI alone, but when it is thought to be involved in the development of CVI and contributing to PLE, investigation to exclude other VM components of the KTS is necessary.<sup>255, 256</sup>

In evaluation of CLI, the functional status of the lymphatic system should be determined first with LSG as the initial baseline investigation, in order to delineate excessive fluid accumulation in the tissues of the limb or affected lymphatic territories. Additional tests are also required when the extratruncular LM is involved in KTS.

CLI due to primary PLE is mostly due to primary lymphedema caused by truncular LM lesions affecting the lymphatic trunk system (e.g. lymphatic dysplasia: aplasia, hypoplasia, or hyperplasia). Extratruncular LM lesions (eg. lymphangioma) on the other hand, are seldom involved in CLI. However, when present, the extratruncular LM may be evaluated with MRI and or whole body blood pool scintigraphy.<sup>47, 118, 247</sup> Other optional tests may be further included depending upon the overall CVM components (e.g. AVM). (Table I)

### **Clinical management**

The general principles of primary PLE management should remain within the guidelines for the management of KTS and its vascular malformation component. However, this combined

venous-lymphatic disorder by two independent VM and LM conditions results in an extremely delicate mutual interdependency; their management mandates proper interpretation of this complicated interrelationship between them.

The management of the CVI should have a priority over that of the CLI unless there is a serious complication of the LM component (e.g. leakage with or without sepsis). This is because the degree and extent of negative impact on CLI by the CVI is much more severe than the effect of the CLI on the CVI. Effective control of the CVI often results in much improved CLI condition.

Baseline therapy for the CLI component of primary PLE is compression therapy since the absolute majority of the CLI is limited to the lymphedema. Reinforced gradient compression therapy based on DLT is required to control the CVI and CLI together.

However, lymphedema caused by CLI in primary PLE is more difficult to control than CLI by independent primary lymphedema with no CVI component. The CLI combined with CVI is often more resistant to the conventional treatment based on DLT, and the disease has a distinct tendency to progress. Therefore, aggressive care with a strict prevention regimen (e.g. infection) is warranted even for maintenance compared to the solitary condition of primary lymphedema.

When this truncular LM causing primary lymphedema is combined with the extratruncular LM (lymphangioma), additional treatment with sclerotherapy of the coexisting extratruncular LM is generally required. When such a lesion is present, it has a direct communication to the lymph transporting system, which produces an additional burden to the truncular LM that already causes the CLI.

Management of the CVI in primary PLE is dependent on its etiology. When the reflux of the MV is the source of CVI, the MV should be treated either with open surgical resection or endovascular obliteration. However, as its precondition, the treatment of the MV warrants a normal deep venous system that can tolerate the sudden influx of diverted blood volume following the obliteration of the MV system.<sup>255-258</sup>

The CVI of primary PLE is occasionally due to deep vein dysplasia, which would require a conservative management unless there is a clear evidence for significant hemodynamic gain by

bypass surgery of the hypoplastic or aplastic iliac and/or femoral veins to relieve venous hypertension in patients with chronic indolent venous ulcers.<sup>240, 241</sup>

However, the benefit of surgery over the basic conservative therapy of CVI in patients with primary PLE (e.g. MV resection) should be carefully weighed against the potential deleterious effects on the coexisting LM with a marginally compensated CLI, which would make the clinical condition worse.

Therefore, primary PLE generated by HLM as the vascular malformation component of KTS should be handled by a multidisciplinary team to manage the extremely delicate interdependency between the VM and LM safely.

Conclusion:

— PLE can be managed more effectively when open and/or endovascular therapy is added to the basic compression therapy to control the CVI and CLI together.

— Primary PLE with CVI by the reflux of MV can be treated successfully with MV resection, while CVI by deep vein dysplasia with the conventional compression therapy alone in its majority.

— Secondary PLE may show regression after repair of the venous pathology<sup>240</sup>

## X. Special Issue: Lipedema - Differential Diagnosis

### Introduction

Lipedema, the most common disorder to be mistaken with lymphedema, is an infrequently recognized clinical entity affecting nearly exclusively women and does not take place in the World Health Organization International Classification of Diseases-10 (WHO ICD-10) as an individual disease.<sup>259</sup>

### Definition

Lipedema is a bilateral, symmetrical, 'bike pant' or column-shaped fatty swelling of the legs, whereas arms are less commonly involved.<sup>260-264</sup> This is a female disorder and males usually develop lipedema on the basis of hormonal disturbance, however there is one published case report where a healthy man was diagnosed with

lipedema.<sup>265</sup> The general incidence of lipedema among women is estimated to be around 11%.<sup>261</sup>

### Pathology and pathophysiology

Földi and Földi have proposed that microangiopathy in the area of the affected adipose tissue results in higher permeability to proteins and increased capillary fragility leading to spontaneous and minor traumatic injury-induced formation of bruising.<sup>261</sup> Siems *et al* detected nearly four-fold higher levels of plasma vascular endothelial growth factor (VEGF) levels at baseline than normal values of plasma VEGF.<sup>266</sup> VEGF controls angiogenesis and hypoxia is a potent inducer of angiogenesis and this factor may have a role in lipedema formation. The detected high baseline levels of both malonyl dialdehyde (MDA) and protein carbonyls are indicative of severe pre-existing oxidative stress and lipid peroxidation.<sup>266</sup> Pit-1 mutation<sup>267</sup> in family members with lipedema and genetic screening of lipedema affected families<sup>268</sup> strongly suggests inheritance. Suga *et al* found robust CD68+ macrophage infiltration in lipedematous adipose tissue with loss of adipocytes due to necrosis and simultaneous proliferation of adipose-derived stem cells (Ki67+ CD34+). These results suggest massive adipogenesis with concomitant hypoxia resulting in necrosis and macrophage recruitment.<sup>269</sup> Lipedema is presumably associated with endocrinological background.<sup>262-264</sup>

However, adipocyte metabolism in lipedema is poorly investigated and remains to be elucidated; it may share similarities with obese white adipose tissue pathophysiology. High fat diet could trigger adipocyte hypertrophy and saturated fatty acid release recruits macrophages inducing inflammatory response.<sup>270</sup> High fat diet plays also an important role in stem cell recruitment.<sup>271</sup> Relatively high prevalence of lipedema among congenital analbumenic patients might be explained with abnormal lipid metabolism.<sup>272</sup> Suspected subclinical, later clinical lymphatic insufficiency may further aggravate the enlargement of adipose tissue as seen in animal models.<sup>273, 274</sup>

### Clinical Findings

The diagnosis of lipedema is relatively simple using patient history and clinical examina-

tion.<sup>260-264</sup> There are striking features to facilitate the recognition of this disproportional obesity. In the early stages of the disorder, the only clues may be the bilateral fat-pads right below the inner sides of the knees and the disappearance of the concave spaces on both sides of the Achilles tendon (ie, the filling of the retromalleolar sulcus).<sup>261-263</sup> On progression the characteristic stove pipe legs appear, however, the feet remain spared and the fat deposits begin abruptly above the ankles (cuffing sign)<sup>4,5</sup>. In case of arm involvement fat deposition abruptly ends at wrists leaving hands unaffected.<sup>4,5</sup> In contrast to lymphedema, Stemmer's sign is always negative in pure lipedema and the oedema is hardly or non-pitting.<sup>261-264</sup> Two further leading hallmarks are the 'easy bruising' and aching dysaesthesia.<sup>261-264</sup>

Lipedema, especially in advanced stages, is quite frequently combined with impaired lymphatic or venous function that may strongly modify the original limb shape resembling the features of identical vascular abnormality.<sup>262-264, 275</sup>

### **Clinical appearance**

Földi and Földi proposed 2 two types of lipedema phenotype<sup>3</sup>: columnar and lobar whereas the first type seems to be predominant and can be described as enlargement of portions of the lower limbs as a series of varying conic sections and the combination of the two appearances is also not uncommon.

### **Classification**

In stage I, the skin looks flat, but the subcutis is already enlarged and on palpation feels like 'styrofoam balls in a plastic bag'. In stage II, walnut- to apple-sized indurations develop and the overlying skin has an irregular surface ('mattress phenomenon'). Stage III shows larger indurations and deforming, even lobular fat deposits. The same group recommended a classification concurring with the location of the fat deposits: mainly buttocks (type I), buttocks to knees (type II), buttocks to ankles (type III), mainly arms (type IV) and mainly lower legs (type V).<sup>276</sup>

Schingale distinguishes five types of lipedema presentation: type I: adipose tissue increased on buttocks and thighs, type II: the lipedema extends to the knees with formation of fat pads on the in-

ner side of the knees, type III: lipedema extends from the hips to the ankles, type IV: involving the arms and legs, type V: lipolymphedema.<sup>277</sup>

### **Disease course**

Manifestation of lipedema usually starts after puberty or pregnancy; in rare cases it may manifest after menopause.<sup>261-264</sup> In most cases the disease has a progressive course with gradually increasing fat deposition.

### **General principles of diagnostic tests**

In most cases lipedema could be easily diagnosed. However, combined forms with lymphatic or venous insufficiency, morbid obesity could be cumbersome, therefore various non- or minimally invasive tests might efficiently assist clinical assessment.

### **Non-invasive evaluation**

#### *Waist-to-Height Ratio*

Of the anthropometric measurements waist-to-height ratio is a practical tool for a discrimination between obesity and lipedema.<sup>278</sup>

#### *Waist-to-Height Ratio values (Nauheimer adiposity scale)<sup>278</sup>*

<0.40	underweight
0.40-0.45	normal
0.46-0.54	overweight
0.55-0.63	weak obesity = grade 1 by BMI
0.64-0.72	moderate obesity = grade 2 by BMI
0.73-0.81	severe obesity = grade 3 by BMI
0.82-0.90	massive obesity = grade 4 by BMI
>0.91	giant obesity = grade 5 by BMI

#### *Streeten Test*

After the exclusion of cardiac, renal and venous insufficiency the patient can be subjected to this examination. The person drinks 20 ml water/body-weight kg and remains in an upright position for 4 hours. During this observational period urine is collected. The leg volumetry is scheduled prior and subsequent to test. Normal healthy persons excrete more than 60% of the ingested water and the leg volume does not in-

crease with more than 350 ml/kg.<sup>279</sup> Due to the unpractical and exhausting procedure for the patient this test is hardly used any more.

### *Capillary Fragility Assessment*

Bruising is attributed to increased capillary fragility in lipedema. Capillary fragility is decreased when patients are subjected to efficient decongestion.<sup>280</sup> Another clinical setting compared uncomplicated simple obesity with uncomplicated lipedema from the perspective of capillary fragility measurement and disclosed that the capillaries of lipedematous limbs are much more sensitive to physical injuries (unreported data).

### *Assessment of Aortic Stiffness in Lipedema*

Transthoracic echocardiography and blood pressure measurement revealed that lipedema was associated with higher aortic stiffness compared to healthy individuals.<sup>281</sup>

### *Pain Perception Assessment*

Spontaneous pain was described as pressing and 'lumpish' by most lipedema patients; other sensory and affective pain characterizations were heavy, tearing, distressing, enervating, fierce, unbearable, exhausting, and pinching.<sup>282</sup> The pinch test is the most simple method for pain provocation.<sup>261</sup>

In a comparative clinical trial a 10-item questionnaire specifically constructed for an accurate characterization of lipedema as well as a special numerical analogue scale (from 0 to 10) called pain rating scale and Wong Baker Faces scale were applied for pain assessment and clearly showed that decongestion was able to improve pain perception.<sup>283</sup>

### *Ultrasound Examination*

High resolution ultrasonography can distinguish lipedema from phleb- or lymphedema with high sensitivity.<sup>284</sup>

### *CT, MRI Examination*

CT<sup>285</sup> and MRI<sup>286</sup> are indicated for scientific purposes or subtle cases. According to Monnin-

Delhom *et al.*, computed tomography scan has a sensitivity of 95% and specificity of 100% for the diagnosis of lipedema.<sup>285</sup>

### **Minimally invasive evaluation:**

#### *Lymphoscintigraphy and Fluorescent Microlymphography:*

Altered microcirculation with increased permeability results a large amount of interstitial fluid thus increased lymph flow is visualized by lymphoscintigraphy in early stages of lipedema. If lipedema remains untreated the increasing amount of interstitial fluid warrants a higher transport capacity of lymphatic conductors. This transitional intensive function exhausts the lymphatic vessels modifying the phenotype from lipedema to lipo-lymphedema as a result of lymphatic insufficiency.<sup>287</sup>

Fluorescent microlymphography displays lymphatic microaneurysms and dilated vessels of the uppermost lymphatic network, indicating that lymph vessels might also be involved in the pathogenesis.<sup>288</sup>

#### *MRI lymphangiography*

This examination is capable of the evaluation of various tissue components and simultaneous display of the lymphatic vessels with high precision.<sup>289</sup>

### **Treatment**

#### *Non-surgical treatment*

Even if lipedema is not very responsive to dietary restrictions weight control is of paramount importance in lipedema care in order to improve symptoms and to prevent progression.<sup>261-263</sup>

The intensive phase of conservative treatment corresponds to decongestive lymphatic therapy (DLT).<sup>261</sup> The first observational study on the effect of DLT in lipedema showed that the maximally achieved reduction was nearly 10% of the original leg girth.<sup>290</sup> In a clinical study manual lymph drainage (MLD)-based DLT was compared with MLD+sequential intermittent pneumatic compression (SIPC)-based DLT. Each treatment regimen resulted in significant limb volume loss without any difference between the two modali-

ties.<sup>291</sup> In other controlled trials MLD+SIPC-based DLT decreased capillary fragility<sup>280</sup> and pain perception<sup>283</sup>, as well.

The maintenance phase aims to preserve volume decrease using medical compression pantyhoses. A dogmatic concept discourages the use of high compression class stockings as lipedematous limbs do not tolerate high pressure. A recent study utilizing chronic venous insufficiency questionnaire (CIVIQ) of 20 items and visual analogue scale (VAS) was able to show that lipedema patients displayed almost the same level of tolerance to 23-32 mmHg (lower) and 34-46 mmHg (higher) pressures.<sup>292</sup>

### *Surgical treatment*

Tumescent liposuction with vibrating micro-cannulas as surgical approach gives a reliable and long-time benefit including robust volume reduction along with a reduction of oedema and pain to lipedema patients without proven damage of lymphatics.<sup>293</sup>

### **Prognosis**

Early diagnosis and treatment are mandatory for lipedema otherwise gradual enlargement of fatty deposition causes impaired mobility, debilitating condition and further co-morbidities like arthrosis and lymphatic insufficiency. When lipedema is combined with advanced lymphedema interlobar areas may become susceptible for microbial infections that may further progress to cellulitis or septicaemia.

Lipedema has remarkable psychological and psychiatric impact ranging from mild to severe anxiety, depression, or even anorexia.<sup>261-264</sup>

## **XI. Summary**

Accurate diagnostic programs and tools and enhanced awareness of the early signs of lymphedema are essential. Primary lymphedema can be managed safely as one of the chronic lymphedemas by a proper combination of DLT with compression therapy regardless of the clinical stage of lymphedema. Treatment in the maintenance phase should include compression garments, self management including the com-

pression therapy, self massage and meticulous personal hygiene and skin care in addition to lymph-transport promoting exercises. Prevention of chronic lymphedema in patients at risk is critical. Early diagnostic programs and enhanced awareness should be fully integrated.

The management of primary lymphedema can be further improved with proper addition of surgical therapy either reconstructive or ablative. These two surgical therapies can be effective only when fully integrated with MLD-based DLT postoperatively unless reconstructive surgery is performed as a preventive intervention (e.g. LVA in patients at risk of lymphedema but without clinical signs of swelling).<sup>200</sup>

Excisional surgery is a very effective method to control the progression of lymphedema initially, but ultimately becomes unable to maintain its initial success without additional DLT postoperatively. Liposuction for decompression will also have the same outcome; postoperative maintenance compression is mandated.

Compliance with a long-term commitment of DLT postoperatively is the most critical factor determining the success of any new treatment strategy with either reconstructive or palliative surgery. The future of management of primary lymphedema caused by tuncular lymphatic malformation has never been brighter with the new prospect of gene-oriented management.

“Molecular antidotes” to such pathological overgrowth of lymphangiomas such as the Klippel Trenaunay Syndrome should become major players, with a chance for cure, in near future.

## **Epilogue**

We tried to provide general and broad concepts regarding primary lymphedemas. We also tried to leave minimum points of disagreement as possible, thus providing the reader some indisputable points that one can trust and apply to their clinical practice as phlebologists.

Attempt to reduce the length of the document to improve its efficacy of the delivery, might have made the document poorer in new ideas and insights, but all points considered will have a greater strength as recommendations.

B.B. LEE, MD, PhD, FACS  
*Coordinator*

## References

1. Guyatt GH, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, *et al*: Grading strength of recommendations and quality of evidence in clinical guidelines. *Chest* 2006;129:174-181.
2. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, *et al*: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-926.
3. The diagnosis and treatment of peripheral lymphedema: Consensus document of the International Society of Lymphology. *Lymphology* 2003;36(2):84-91.
4. 2009 Consensus Document of the International Society of lymphology: The diagnosis and Treatment of Peripheral Lymphedema. *Lymphology* 2009; 42:51-60.
5. International Lymph Framework: Best practice for the management of lymphoedema. 2<sup>nd</sup> Edition 2012. [www.lympho.org](http://www.lympho.org)
6. Campisi C, Michelini S, Boccardo F. Guidelines of the Italian Society of Lymphology 2004;37(4):182-4.
7. Mortimer PS. Therapy approaches for lymphedema. *Angiology*. 1997;48(1):87-91.
8. Foldi E. The treatment of lymphedema. *Cancer*. 1998;83(12):2833-4.
9. Leduc O, Leduc A, Bourgeois P, Belgrado JP. The physical treatment of upper limb edema. American Cancer Society Lymphedema Workshop; *Cancer* 1998;83(12):2835-2839.
10. Szolnoky G, Lakatos B, Keskeny T, Dobozy A. Advantage of combined decongestive lymphatic therapy over manual lymph drainage: a pilot study. *Lymphology* 2002;35(1):277-282.
11. Rockson SG, Miller LT, Senie R *et al*. American cancer society lymphoedema workshop. workgroup iii: diagnosis and management of lymphoedema. *Cancer* 1998; 83(12): 2882-5.
12. Lee BB, Kim YW, Kim DI, Hwang JH, Laredo J, Neville R: Supplemental surgical treatment to end stage (stage IV -V) of chronic lymphedema. *Int Angiol*. 2008; 27(5):389-95.
13. Baumeister RGH, Siuda S. Treatment of lymphedemas by microsurgical lymphatic grafting: what is proved? *Plastic and Reconstructive Surgery* 1990;85:64-74.
14. Campisi C, Boccardo F, Zilli A, Maccio A, Gariglio A, Schenone F. Peripheral lymphedema: new advances in microsurgical treatment and long-term outcome. *Microsurgery*. 2003;23(5):522-5.
15. Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child AH. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. *J. Med. Genet.* 2003;40: 697-703
16. Brice G, Mansour S, Bell R, Collin JRO, Child A H, Mortimer P, *et al*. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. *J. Med. Genet.* 2002;39: 478-483
17. Burnand KG, Mortimer PS. Lymphangiogenesis and genetics of lymphoedema. In: Browse N, Burnand KG, Mortimer PS, editors. *Diseases of the lymphatics*. London: Arnold; 2003. pp. 102-9.
18. Witte MH, Erickson R, Reiser FA, Witte CL. Genetic alterations in lymphedema. *Phlebology* 1997;16:19-25.
19. Bruna J, Miller AJ, Beninson J. The clinical grading and simple classification of lymphedema. *Lymphology* 2002;35:160-162.
20. Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. *Vasc Med*. 1998;3(2):145-56.
21. Connell F, Gordon K, Brice G, Keeley V, Jeffery S, Mortimer P, Mansour S, Ostergaard P. The classification and diagnostic algorithm for primary lymphatic dysplasia: an update from 2010 to include molecular findings. *Clin Genet*. 2013. Apr 26. doi: 10.1111/cge.12173. (Epub).
22. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. *Cardiovasc Res* 2010;87:198-210.
23. Levick JR. An introduction to cardiovascular physiology 5th edition, 2010; Hodder Arnold, London pp 204-12.
24. Stanton AW, Patel HS, Levick JR, *et al*. Increased dermal lymphatic density in human leg compared with forearm. *Microvasc Res* 1999; 57: 320-328.
25. Olszewski WL, Engeset A. Intrinsic contractility of pre- and lymph vessels and lymph flow in human leg. *Am J Physiol* 1980;239:775-783.
26. Tanaka H, Zaima N, Sasaki T, Yamamoto N, Sano M, Konno H, Setou M, Unno N. Loss of lymphatic vessels and regional lipid accumulation is associated with great saphenous vein incompetence. *J Vasc Surg* 2012;55:1440-1448
27. Dennis, R Haemodynamics of Lymphoedema. *Journal of Lymphoedema* 2008; 3(2): 45-49
28. Rockson SG. Lymphedema. *Am J Med*. 2001;110(4):288-95.
29. Lammie PJ, Cuenco KT, Punkosdy GA. The pathogenesis of filarial lymphedema: is it the worm or is it the host? *Ann N Y Acad Sci*. 2002;979:131-42; discussion 188-96.
30. Lee BB: Lymphoedeme post-chirurgical: un terme frappe d'interdiction pour les chirurgiens. *Angeologie* 2004;6(4):7-8.
31. Bernas MJ, Witte CL, Witte MH. The diagnosis and treatment of peripheral lymphedema. *Lymphology* 2001;34:84-91.
32. Lee BB, Seo JM, Hwang JH, Do YS, Kim DI, Byun HS, *et al*: Current concepts in lymphatic malformation (LM). *J. VascEndovasc Surg* 2005;39(1):67-81.
33. Lee BB: Lymphedema-Angiodysplasia Syndrome: a Prodigal form of Lymphatic Malformation (LM). *Phlebology* 2005; 47:324-332.
34. Papendieck CM. Lymphangiomas and dermoepidermal disturbances of lymphangiadenodysplasias. *Lymphology* 2002;35:478-85.
35. Vercellio, Baraldini V, Coletti M, Santuari D. Strategies in early management of pure lymphatic malformations. *Lymphology* 2002;35:472-477.
36. Rosbotham JL, Brice GW, Child AH, Nunan TO, Mortimer PS, Burnand KG. Distichiasis-lymphoedema: clinical features, venous function and lymphoscintigraphy. *Br J Dermatol*. 2000;142:148-52.
37. Northrup KA, Witte MH, Witte CL. Syndromic classification of hereditary lymphedema. *Lymphology* 2003;36:162-89.
38. Greenlee R, Hoyme H, Witte M, Crowe P, Witte C. Developmental disorders of the lymphatic system. *Lymphology* 1993;26:156-168.
39. Aagaens O, van der Hagen CB, Refsum S. Hereditary recurrent intrahepatic cholestasis from birth. *Arch Dis Child*. 1968;43:646-57.
40. Lee BB, Laredo J, Seo JM, Neville R: Treatment of Lymphatic Malformations. Chapter 29, Hemangiomas and Vascular Malformations. Mattassi, Loose, Vaghi (eds) Springer-Verlag Italia, 2009, Milan, Italy pp. 231-250
41. Lee BB: Statues of new approaches to the treatment of congenital vascular malformations (cvms) – single center experiences – (editorial review). *Eur. J Vasc Endovasc Surg* 2005;30(2):184-197.
42. Lee BB: Advanced management of congenital vas-

- cular malformation (CVM). *International Angiology* 21(3):209-213, September 2002.
43. Lee BB, Bergan JJ: Advanced management of congenital vascular malformations: a multidisciplinary approach. *Cardiovasc Surg* 2002;10(6):523-33.
44. Lee BB. Critical issues on the management of congenital vascular malformation. *Annals Vasc Surg* 2004;18(3):380-392.
45. Lee BB: Current concept of venous malformation (VM). *Phlebology* 2003;43:197-203.
46. Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results. *J Vasc Surg* 2003;37(3):533-8.
47. Lee BB, Mattassi R, Choe YH, Vaghi M, Ahn JM, Kim DI, *et al.* Critical role of duplex ultrasonography for the advanced management of a venous malformation (VM). *Phlebology* 2005; 20:28-37.
48. Lee BB, Do YS, Yakes W, Kim DI, Mattassi R, Hyun WS, *et al.* Management of arterial-venous shunting malformations (AVM) by surgery and embolosclectherapy. A multidisciplinary approach. *J. Vasc. Surg* 2004;39(3):590-600.
49. Lee B B, Laredo J, Neville R. Arterio-venous malformation: how much do we know? *Phlebology* 2009;24:193-200
50. Lee, B.B., Laredo, J., Deaton, D.H., and Neville, R.F. Arteriovenous malformations: evaluation and treatment. In *Handbook of Venous Disorders: Guidelines of the American Venous Forum*, 3rd Edition; Gloviczki, P., Ed; A Hodder Arnold Ltd, 2009, London, UK.
51. Goldman MP, Fitzpatrick RE, Ruiz-Esparza J. Treatment of port-wine stains (capillary malformation) with the flashlamp-pumped pulsed dye laser. *J Pediatr*. 1993;122(1):71-7.
52. Berwald C, Salazard B, Bardot J, Casanova D, Magalon G. Port wine stains or capillary malformations: surgical treatment *Ann Chir Plast Esthet.* 2006;51(4-5):369-72.
53. Gloviczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. *Phlebology.* 2007; 22: 291-298.
54. Jacob AG, Driscoll DJ, Shaughnessy WJ, Stanson AW, Clay RP, Gloviczki P. Klippel-Trenaunay syndrome: spectrum and management. *Mayo Clin Proc.* 1998;73(1):28-36.
55. Lee BB, Bergan J, Gloviczki P, Laredo J, Loose DA, Mattassi R, Parsi K, Villavicencio JL, Zamboni P: Diagnosis and treatment of venous malformations - Consensus Document of the International Union of Phlebology (IUP)-2009. *Int Angiol* 2009;28(6):434-51. Lee BB, Laredo J, Lee TS, Huh S, Neville R. Terminology and classification of congenital vascular malformations. *Phlebology.* 2007;22(6):249-52.
56. Belov S. Classification, terminology, and nosology of congenital vascular defects. In: Belov S, Loose DA, Weber J, eds. *Vascular Malformations*. Reinbek, Germany: Einhorn-Press; 1989 pp.25-30.
57. Belov St. Classification of congenital vascular defects. *Int Angiol* 1990;9:141-146.
58. Kinmonth JB, Wolfe JH. Fibrosis in the lymph nodes in primary lymphoedema. Histological and clinical studies in 74 patients with lower-limb oedema. *Ann R Coll Surg Engl.* 1980;62(5):344-354.
59. Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, *et al.* Hereditary lymphedema: evidence for linkage and genetic heterogeneity. *Hum. Mol. Genet.* 1998;7:2073-2078.
60. Michelini S, Degiorgio D, Cestari M, *et al.* Clinical and genetic study of 46 Italian patients with primary lymphedema. *Lymphology* 2012; 45(1):3-12.
61. Brice G, Child AH, Evans A, Bell R, Mansour S, Mortimer P, *et al.* Milroy disease and the VEGFR-3 mutation phenotype. *J. Med. Genet.* 2005;42:98-102.
62. Ferrell RE, Baty CJ, Kimak Ma, Karlsson JM, Lawrence EC, Franke-Snyder M, *et al.* GJC2 missense mutations cause human lymphedema. *Am J Hum Genet* 2010;86: 943-8.
63. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Mortimer PS, *et al.* Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). *Nat. Genet.* 2011;43:929-931.
64. Witte MH, Erickson R, Bernas M, *et al.* Phenotypic and genotypic heterogeneity in familial Milroy lymphedema. *Lymphology* 1998;31:145-55.
65. Ghalamkarpour A, Holnthoner W, Saharinen P, Boon L M, Vikkula M, *et al.* Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. *J Med Genet* 2009;46:399-404.
66. Erickson RP. Lymphedema-distichiasis and FOXC2 gene mutations. *Lymphology.* 2001;34(1):1-5.
67. Samlaska CP. Congenital lymphedema and distichiasis. Distichiasis-lymphedema. A hereditary syndrome of multiple congenital defects. *Pediatr Dermatol.* 2002;19(2):139-41.
68. Finegold DN, Kimak MA, Lawrence EC, Levinson KL, Cherniske EM, Pober BR, Dunlap JW, Ferrell RE. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. *Hum Mol Genet.* 2001;15(10):1185-9.
69. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, *et al.* Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nat. Genet.* 2000;25:153-159.
70. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *Am. J. Hum. Genet.* 2000;67:295-301.
71. Mangion J, Rahman N, Mansour S, Brice G, Rosbotham J, Mortimer P, *et al.* A gene for Lymphedema-distichiasis maps to 16q24.3. *Am. J. Hum. Gen.* 1999;65:427-432.
72. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, *et al.* Mutations in FOXC2 (MFH-1), a fork-head family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *Am. J. Hum. Genet.* 2000;67:1382-8.
73. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Vikkula M *et al.* Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. *Am. J. Hum. Genet.* 2003;72:1470-8.
74. Alders M, Hogan BM, Gjini E, Salehi F, Al-Gazali L, Witte M, *et al.* Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. *Nat Genet.* 2009;41:1272-4.
75. Connell F, Kalidas K, Ostergaard P, Brice G, Homfray T, Mortimer PS, *et al.* Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. *Human Genetics.* 2010;127:231-41.
76. Ostergaard P, Simpson MA, Brice G, Mansour S, Connell F, Mortimer PS, *et al.* Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. *J Med Genet.* 2011;48:251-5.
77. Ostergaard P, Simpson M, Mendola A, Vasudevan P, Connell FC, Mortimer PS, *et al.* Mutations in KIF11 Cause Autosomal-Dominant Microcephaly Variably Associated with Congenital Lymphedema and Chorioretinopathy. *Am. J. Hum. Gen.* 2012; doi:10.1016/j.ajhg.2011.12.018.
78. Bos FL, Caunt M, Peterson-Maduro J, Planas-Paz L, Kowalski J, Karpanen T, *et al.* CCBE1 is essential for

- mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C *in vivo*. *Circ Res*. 2011;109(5):486-91.
79. Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, van der Hagen CB, *et al*. Mapping of the Locus for Cholestasis-Lymphedema Syndrome (Aagenaes Syndrome) to a 6.6-cM Interval on Chromosome 15q Am J Hum Genet. 2000; 67(4):994-999.
  80. Ferrell RE, Finegold DN. Research perspectives in inherited lymphatic disease: an update. *Ann N Y Acad Sci* 2008;1131:134-39.
  81. Rockson SG. Secondary lymphedema: Is it a primary disease? *Lymphatic Research and Biology* 2008;6(2):63-64
  82. Rockson SG. Diagnosis and management of lymphatic vascular disease *J Am Coll Cardiol*. 2008;52(10):799-806
  83. Finegold D, Baty C, Knickelbein K, Perschke S, Noon S, *et al*. Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. *Clin Cancer Res* 2008;18:232-2390.
  84. Mortimer PS, Levick JR. Chronic peripheral oedema: the critical role of the lymphatic system. *Clin Med* 2004; 4: 3448-53
  85. Mellor RH, Hubert CE, Stanton AW, Tate N, Akhras V, Smith A, Burnand KG, Jeffery S, Mäkinen T, Levick JR, Mortimer PS. Lymphatic dysfunction, not aplasia, underlies Milroy disease. *Microcirculation*. 2010;17:281-296.
  86. Lee BB, Laredo J: Contemporary role of lymphoscintigraphy: we can no longer afford to ignore! *Editorial, Phlebology* 2011;26:177-178
  87. Lee BB: Chronic lymphedema, no more stepchild to modern medicine! *Eur J Lymphol* 2004;14 (42):6-12.
  88. Lee BB, Kim DI, Whang JH, Lee KW. Contemporary management of chronic lymphedema – personal experiences. *Lymphology* 2002;35:450-455
  89. Lee BB: Current issue in management of chronic lymphedema: Personal Reflection on an Experience with 1065 Patients. *Lymphology* 2005;38:28-31.
  90. Lee BB, Laredo J, Neville R, Loose D: Diagnosis and management of primary phlebolymphedema. Chapter 64. Section – XVI - Phlebolymphedema. *LYMPHEDEMA: A Concise Compendium of Theory and Practice*. Lee, Byung-Boong; Bergan, John; Rockson, Stanley G. (Eds.), 1st Edition, Springer-Verlag, London, UK, 2011, pp 537-546.
  91. Lee BB, Andrade M, Bergan J, Boccardo F, Campisi C, Damstra R, Flour M, Gloviczki P, Laredo J, Pillar N, Michelini S, Mortimer P, Villavicencio JL : Diagnosis and treatment of Primary Lymphedema - Consensus Document of the International Union of Phlebology (IUP)-2009. *International Angiology* 2010;29(5): 454-70.
  92. Lee BB, Bergan, JJ: New clinical and laboratory staging systems to improve management of chronic lymphedema. *Lymphology* 2005;38(3):122-129.
  93. Michelini S., Campisi C., Gasbarro V., Allegra C., Conte M., Cestari M., Molisso A., Cavezzi A., Mattassi R., Aiello A., Ricci M., Zanetti L. National guidelines on lymphedema. *Lymphology* 2007;55:238 – 242.
  94. Michelini S., Failla A., Moneta G., Campisi C. Boccardo F. Clinical staging of lymphedema and therapeutical implications. *Lymphology* 2002;35:168-176.
  95. Michelini S., Failla A., Moneta G. Lymphedema : epidemiology, disability and social costs. *Lymphology* 2002;35:169-171.
  96. Michelini S., Failla A., Moneta G., Rubeghi V., Zinicola V., M. Cardone, *et al*. Lymphedema and occupational therapy. *Lymphology* 2007;55: 243-246.
  97. Michelini S, Failla A, Moneta G, Zinicola V, Romaldini, Puglisi D. International classification of lymphedema functioning and disability evaluation. *Eur J Lymphol* . 2007;17(51):16-19.
  98. Stemmer R.. A clinical symptom for the early and differential diagnosis of lymphedema. *Vasa*. 1976;5(3):261-2.
  99. Kim YW, Do YS, Lee SH, Lee BB: Risk Factors for Leg Length Discrepancy in Patients with Congenital Vascular Malformation. *J Vasc Surg*. 2006;44:545-53.
  100. Mattassi R, Vaghi M: Vascular bone syndrome-angiosteodystrophy: Current Concept. *Phlebology*. 2007; 22: 287-290.
  101. Tassenoy A, De Mey J, De Ridder F, Van Schuerbeek P, Vanderhasselt T, Lamote J, *et al*. Postmastectomy lymphoedema: different patterns of fluid distribution visualised by ultrasound imaging compared with magnetic resonance imaging. *Physiotherapy*. 2011;97(3):234-43.
  102. Case TC, Witte CL, Witte MH, *et al*. Magnetic resonance imaging in human lymphedema: comparison with lymphangioscintigraphy. *Magn Reson Imaging* 1992;10:549-558.
  103. Haaverstad R, Nilsen G, Myhre HO, Saether OD, Rinck PA. The use of MRI in the investigation of leg oedema. *Eur J Vasc Surg* 1992; 6(2):124-29.
  104. Haaverstad R, Nilsen G, Rinck PA, Myhre HO. The use of MRI in the diagnosis of chronic lymphedema of the lower extremity. *Int Angiol* 1994;13(2):115-18.
  105. Hadjis N. S., Carr D. H., Banks L, Pflugl J. J. The Role of CT in the Diagnosis of Primary Lymphedema of the Lower Limb. *AJR* 1985;144:361-364
  106. Gamba JL, Silverman PM, Ung D, Dunnick NA, Korobkin M. Primary lower extremity lymphedema: CT diagnosis. *Radiology* 1983;149:218-21
  107. Szuba A, Strauss W, Sirsikar SP, Rockson SG. Quantitative radionuclide lymphoscintigraphy predicts outcome of manual lymphatic therapy in breast cancer-related lymphedema of the upper extremity. *Nucl Med Commun*. 2002;23:1171-5.
  108. Solari N, Gipponi M, Stella M, Queirolo P, di Somma, *et al*: Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma. *Melanoma Research* 2009;19(4):243-251.
  109. Cambria RA, Gloviczki P, Naessens JM, Wahner HW. Noninvasive evaluation of the lymphatic system with lymphoscintigraphy: a prospective, semiquantitative analysis in 386 extremities. *J Vasc Surg*. 1993;18:773-82.
  110. Lohrmann C, Foeldi E, Speck O, Langer M. High-resolution MR lymphangiography in patients with primary and secondary lymphedema. *AJR Am J Roentgenol*. 2006;187(2):556-61.
  111. Lohrmann C, Felmerer G, Foeldi E, Bartholomä JP and Langer M. MR lymphangiography for the assessment of the lymphatic system in patients undergoing microsurgical reconstructions of lymphatic vessels. *Microvascular Research* 2008;76(1): 42-45.
  112. Allegra C, Sarcinella R, Bartolo M Jr. Morphologic and functional changes of the microlymphatic network in patients with advancing stages of primary lymphedema. *Lymphology*. 2002;35(3):114-20.
  113. Bollinger A, Jäger K, Sgier F, Seglias J. Fluorescence microlymphography. *Circulation*. 1981;64(6):1195-2000
  114. Unno N, Nishiyama M, Suzuki M, Yamamoto N, Inuzuka K, Sagara D, Tanaka H, Konno H. Quantitative lymph imaging for assessment of lymph function using indocyanine green fluorescence lymphography. *Eur J Vasc Endovasc Surg*. 2008;36(2):230-6.
  115. Proulx ST, Luciani P, Derzsi S, Rinderknecht M, Mumprecht V, Leroux JC, *et al*. Quantitative imaging of

- lymphatic function with liposomal indocyanine green. *Cancer Res.* 2010;15;70(18):7053-62.
116. Partsch H, Urbanek A, Wenzel-Hora B. The dermal lymphatics in lymphoedema visualized by indirect lymphography. *Br J Dermatol.* 1984;110(4):431-8.
  117. Lee BB, Mattassi R, Kim BT, Kim DI, Ahn JM, Choi JY. Contemporary diagnosis and management of venous and AV shunting malformation by whole body blood pool scintigraphy. *Int. Angiol.* 2004;23(4):355-67.
  118. Deltombe T, Jamart J, Recloux S, Legrand C, Vandembroeck N, Theys S, *et al.* Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. *Lymphology* 2007; 40:26-34
  119. Sergi G, Bussolotto M, Perini P, Calliari I, *et al.* Accuracy of bioelectrical bioimpedance analysis for the assessment of extracellular space in healthy subjects and in fluid retention states. *Ann Nutr Metab* 1994;38(3):158-65
  120. Criado E, Farber MA, Marston WA, Daniel PF, Burnham CB, Keagy BA. The role of air plethysmography in the diagnosis of chronic venous insufficiency. *J Vasc Surg.* 1998;27(4):660-70.
  121. Brorson H. Liposuction in arm lymphedema treatment. *Scand J Surg.* 2003;92(4):287-95.
  122. Brorson H. Liposuction gives complete reduction of chronic large arm lymphedema after breast cancer. *Acta Oncol.* 2000;39(3):407-20.
  123. Antignani PL, Benedetti Valentini F, Aluigi L, baroncelli T *et al.* Guidelines of Italian Society for vascular Investigation. *Int Angiol.* 2012; 5:1-78
  124. Gniadecka M. Localization of dermal edema in lipodermatosclerosis, lymphedema, and cardiac insufficiency. *J Am Acad Dermatol* 1996;35: 37-41
  125. Consensus document of the International Society of Lymphology Executive Committee. The diagnosis and treatment of peripheral lymphedema. *Lymphology* 1995; 28(3):113-17.
  126. Werner GT, Rodiek SO. Value of nuclear magnetic resonance tomography in leg edema of unknown origin. Preliminary report. *Z Lymphol* 1993;17(1):2-5.
  127. Gloviczki P, Calcagno D, Schirger A, *et al.* Noninvasive evaluation of the swollen extremity: experiences with 190 lymphoscintigraphy examinations. *J Vasc Surg.* 1989;9:683-9; discussion 690.
  128. Brautigam P, Foldi E, Schaiper I, Krause T, Vanscheidt W, Moser E. Analysis of lymphatic drainage in various forms of leg edema using two compartment lymphoscintigraphy. *Lymphology* 1998;31:43-55.
  129. Olszewski WL. Lymphoscintigraphy helps to differentiate edema of various etiologies (inflammatory, obstructive, posttraumatic, venous). *Lymphology* 2002;35:233-235.
  130. Guidelines 6.2.0. on lymphoscintigraphy and lymphangiography. page 647. Chapter 58, *Handbook of Venous Disorders: Guidelines of the American Venous Forum*, 3rd Edition; Gloviczki, P., Ed; A Hodder Arnold: London, UK. 2009.
  131. Burnand KM *et al.* Popliteal node visualization during standard pedal lymphoscintigraphy for a swollen limb indicates impaired lymph drainage. *AJR* 2011; 197:1443-8.
  132. Bellini C, Boccardo F, Campisi C, Villa G, Taddei G, Traggiati C, Bonioli E. Lymphatic dysplasias in newborns and children: the role of lymphoscintigraphy. *J Pediatr.* 2008;152(4):587-9.
  133. uami, H, Chang, D Skoracki R, Yamada, K and Kimata, Y Using indocyanine green fluorescent lymphography to demonstrate lymphatic architecture. *Journal of Lymphoedema* 2012;7(2):25-29
  134. Yamamoto T Matsuda, N Doi, K *et al* The earliest finding of indocyanine green lymphography in asymptomatic limbs of lower extremity lymphoedema patients secondary to cancer treatment. *Plastic and Reconstructive Surgery* 2011;128(31):4e-21e.
  135. Campisi C, Bellini C, Eretta C, Zilli A, da Rin E, Davini D, Bonioli E, Boccardo F. Diagnosis and management of primary chylous ascites. *J Vasc Surg.* 2006;43(6):1244-8.
  136. Boccardo F, Bellini C, Eretta C, Pertile D, Da Rin E, Benatti E, Campisi M, Talamo G, Macciò A, Campisi C, Bonioli E, Campisi C. The lymphatics in the pathophysiology of thoracic and abdominal surgical pathology: immunological consequences and the unexpected role of microsurgery. *Microsurgery.* 2007;27(4):339-45.
  137. Gasbarro V, Michelini S, Antignani PL, Tsolaki E, Ricci M, Allegra C. The CEAP-L classification for lymphedemas of the limbs: the Italian experience. *Int Angiol.* 2009;28(4):315-24.
  138. von der Weid PY, Rahman M, Imtiaz MS, van Helden DF. Spontaneous transient depolarizations in lymphatic vessels of the guinea pig mesentery: pharmacology and implication for spontaneous contractility. *Am J Physiol Heart Circ Physiol.* 2008;295(5):1989-2000.
  139. Michelini S, Campisi C, Cavezzi A, Boccardo F, Failla A, Moneta G. National epidemiologic study of lymphedema. *Minerva Cardioangiol.* 1998;46(10):393-4.
  140. Casley-Smith, Judith R, Mason MR, Morgan RG, Casley-Smith JR. Complex physical therapy of the lymphoedematous leg. *Int J Angiol* 1995;4:134-142.
  141. Johansson K, Albertsson M, Ingvar C, Ekdahl C. Effects of compression bandaging with or without manual lymph drainage treatment in patients with postoperative arm lymphedema. *Lymphology.* 1999;32(3):103-10.
  142. Szolnoky G, Mohos G, Dobozy A, Kemeny L: Manual lymphdrainage reduces trapdoor effect in subcutaneous pedicle flaps. *Int J Dermatol* 2006;45:1468-70
  143. Kasseroller RG. The Vodder School: the Vodder method. *Cancer.* 1998;15(83):2840-2.
  144. Foldi E, Foldi M, Weissletter H. Conservative treatment of lymphedema of the limbs. *Angiology* 1985;36:171-180.
  145. Adams KE, Rasmussen JC, Darne C, Tan IC, Aldrich MB, Marshall MV, *et al.* Direct evidence of lymphatic function improvement after advanced pneumatic compression devicetreatment of lymphedema. *Biomed Opt Express.* 2010;15(1):114-125.
  146. Stout N, Partsch H, Szolnoky G, Forner-Cordero I, Mosti G, Mortimer P, *et al.* Chronic edema of the lower extremities: international consensus recommendations for compression therapy clinical research trials. *Int Angiol.* 2012;31(4):316-29.
  147. Hwang JH, Kim TU, Lee KW, Kim DI, Lee BB: Sequential intermittent pneumatic compression therapy in lymphedema. *J. Korean Acad. of Rehab. Med.* 1997;21(1):146-153.
  148. Pflug JJ. Intermittent compression in the management of swollen legs in general practice. *Lancet* 1975;215:69-76.
  149. Partsch H, Stout N, Forner-Cordero I, Flour M, Mofatt C, Szuba A, *et al.* Clinical trials needed to evaluate compression therapy in breast cancer related lymphoedema. Proposals from an expert group. *Int Angiol.* 2010;29(5):442-53.
  150. Lamprou DA, Damstra RJ, Partsch H. Prospective, randomized, controlled trial comparing a new two-component compression system with inelastic multicomponent compression bandages in the treatment of leg lymphedema. *Dermatol Surg.* 2011;37(7):985-91.
  151. Damstra RJ, Partsch H. Prospective, Randomized Con-

- trolled Trial Comparing the Effectiveness of Adjustable Compression Velcro-Wraps *versus* Inelastic Multilayer Compression Bandages in the Initial Treatment of Leg Lymphedema. *J Vasc Surg: Venous and Lym Dis* 2013;1:13-9
152. Partsch H, Damstra RJ, Mosti G. Dose finding for an optimal compression pressure to reduce chronic edema of the extremities. *Int Angiol.* 2011;30(6):527-33.
153. Damstra RJ, Partsch H. Compression therapy in breast cancer-related lymphedema: A randomized, controlled comparative study of relation between volume and interface pressure changes. *J Vasc Surg.* 2009;49(5):1256-63.
154. Mosti G, Picerni P, Partsch H. Compression stockings with moderate pressure are able to reduce chronic leg oedema. *Phlebology.* 2012;27(6):289-96
155. Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens MR. Different physical treatment modalities for lymphoedema developing after axillary lymph node dissection for breast cancer: a review. *Eur J Obstet Gynecol Reprod Biol.*2010;149(1):3-9.
156. McNeely ML, Peddle CJ, Yurick JL, Dayes IS, Mackey JR. Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. *Cancer.* 2011;117(6):1136-48.
157. Devoogdt N, Christiaens MR, Geraerts I, Truijten S, Smeets A, Leunen K, Neven P, Van Kampen M. Effect of manual lymph drainage in addition to guidelines and exercise therapy on arm lymphoedema related to breast cancer: randomised controlled trial. *BMJ.* 2011 Sep 1;343:d5326
158. Moskovitz AH, Anderson BO, Yeung RS, Byrd DR, Lawton TJ, Moe RE. Axillary web syndrome after axillary dissection. *Am J Surg* 2001;181(5):434-9.
159. Lauridsen MC, Christiansen P, Hesselø I. The effect of physiotherapy on shoulder function in patients surgically treated for breast cancer: a randomized study. *Acta Oncol* 2005; 44(5):449-57.
160. Johansson K, Ingvar C, Albertsson M, Ekdahl C. Arm lymphoedema, shoulder mobility and muscle strength after breast cancer treatment - a prospective 2-year study. *Adv Phys Ther* 2001;3:55-66.
161. Olszewski WL, Jain P, Ambujam G, Zaleska M, Cakala M, Gradalski T. Tissue fluid pressure and flow during pneumatic compression in lymphedema of lower limbs. *Lymphat Res Biol.* 2011;9(2):77-83.
162. Mayrovitz HN. Interface pressures produced by two different types of lymphedema therapy devices. *Phys Ther.* 2007;87(10):1379-88.
163. Guidelines 6.3.0. on medical and physical therapy. page 655. Chapter 59, *Handbook of Venous Disorders: Guidelines of the American Venous Forum, 3rd Edition*; Gloviczki, P., Ed; A Hodder Arnold: London, UK. 2009.
164. Roztocil K, Pretovsky I, Olivia I. The effects of hydroethylrutosides on capillary filtration rate in the lower limbs of man. *Eur J Clin Pharm* 1993;11:435-438.
165. Clement DL. Management of venous edema: Insights from an international task force. *Angiology* 2000;51:13-17.
166. Knight KR, Khazanchi RK, Pederson WC *et al.* Coumarin and 7-hydroxycoumarin treatment of canine obstructive lymphoedema. *Clinic Sci.* 1989;77(1): 69-76.
167. Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzoflavone. *N Engl J Med* 1993;329:1158-1163.
168. Burgos A, Alcaide A, Alcoba C *et al.* Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. *Lymphology* 1999;32:3-10.
169. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. *N Engl J Med.* 1999; 340(5):346-350.
170. Piller NB, Morgan RG, Casley-Smith JR. A double-blind, cross-over trial of O-(beta hydroxyethyl)-rutosides (benzo-pyrones) in the treatment of lymphoedema of the arms and legs. *Br J Plast Surg.* 1988;41:20-27.
171. Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. *Cochrane Database Syst Rev.* 2004;(2):CD003140.
172. Michelini S, Campisi C, Failla A, Boccardo F, Moneta G. Combination treatment of lymphedema; Our experiences. *Minerva Cardioangiol.* 1998;46(10):395-6.
173. Campisi C., Boccardo F., Macciò A., Zilli A., Michelini S. Natural coumarins in lymphatic microsurgery. *Lymphology* 2002;35:635 -639.
174. Michelini S., Failla A., Moneta G., Cardone M., Fiorentino A., Michelotti L., Galluccio A. Shockwave therapy in lymphedema patients : preliminary study. *Lymphology* 2007;55: 235 - 237.
175. Farinola N, Piller N. Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema *Lymphat Res Biol.* 2005;3(2):81-6.
176. Olszewski WL. The treatment of lymphedema of the extremities with microsurgical lympho-venous anastomoses. *Int Angiol.* 1988;7(4):312-21.
177. Becker C, Hidden G, Godart S, Maurage H, Pecking A.. Free lymphatic transplantation. *European J. Lymphol.* 1991;6(2): 75-80.
178. Gloviczki P. Review. Principles of surgical treatment of chronic lymphoedema. *Int Angiol.* 1999;18(1):42-6.
179. Becker C, Hidden G, Pecking A *et al.* Transplantation of lymph nodes: an alternative method for treatment of lymphoedema. *Progress in Lymphology* 1990;XI: 487-493.
180. Kim DI, Lee BB, Huh S, Lee SJ, Hwang JH, Kim YI. Excision of subcutaneous tissue and deep muscle fascia for advanced lymphedema. *Lymphology* 1998;31:190-194.
181. Auchincloss H. New operation for elephantiasis. *Puerto Rico J Publ Health & Trop. Med* 1930;6:149-52.
182. Homans J. The treatment of elephantiasis of the legs. *N Engl J Med* 1936;215:1099-1103.
183. Sistrunk WE. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. *Plast Reconstr Surg.* 1998;102(4):1058-67; discussion 1068.
184. Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. *Plast Reconstr Surg.* 1998;102(4):1058-67; discussion 1068.
185. Brorson H, Svensson H, Norrgren K, Thorsson O. Liposuction reduces arm lymphedema without significantly altering the already impaired lymph transport. *Lymphology.* 1998;31(4):156-72.
186. Lee BB, Villavicencio JL: Primary lymphedema and lymphatic malformation: are they the two sides of the same coin? *Eur J Vasc Endovasc Surg* 2010;39:646-653
187. Lee BB, Laredo J, Neville R.: Primary lymphedema as a truncular lymphatic malformation. Chapter 51, Section XI - Lymphedema and Congenital Vascular Malformation Page 419-426, *LYMPHEDEMA: A Concise Compendium of Theory and Practice.* Lee, Byung-Boong; Bergan, John; Rockson, Stanley G. (Eds.), 1st Edition, Springer-Verlag, London, UK, 2011
188. Lee BB, Laredo J, Neville R, Mattassi R: Primary

- lymphedema and Klippel-Trenaunay syndrome. Chapter 52. Section XI - Lymphedema and Congenital Vascular Malformation. Page 427-436, LYMPHEDEMA: A Concise Compendium of Theory and Practice. Lee, Byung-Boong; Bergan, John; Rockson, Stanley G. (Eds.), 1st Edition, Springer-Verlag, London, UK, 2011
189. Lee BB, Laredo J. Classification of congenital vascular malformations: the last challenge for congenital vascular malformations. *Phlebology*. 2012;27(6):267-9.
  190. Campisi C, Da Rin E, Bellini C, Bonioli E, Boccardo F. Pediatric lymphedema and correlated syndromes: role of microsurgery. *Microsurgery*. 2008;28(2):138-42.
  191. Campisi C, Boccardo F. Vein graft interposition in treating peripheral lymphoedemas. *Handchir Mikrochir Plast Chir*. 2003;35(4):221-4.
  192. Campisi C, Bellini C, Campisi C, Accogli S, Bonioli E, Boccardo F. (2010). Microsurgery for lymphedema: clinical research and long-term results. *Microsurgery*, vol. 30(4), p. 256-260.
  193. Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphatic-venous microsurgery. *World J Surg*. 2004;28(6):609-13.
  194. Lee BB, Laredo J, Neville R: Current Status of Lymphatic Reconstructive Surgery for Chronic Lymphedema: It Is Still an Uphill Battle! *Int J Angiol* 2011;20(2): 73-79.
  195. Lee BB, Laredo J, Neville R: Current dilemma with controversy. Chapter 45. Section IX - Surgical treatment - Reconstructive Surgery Section, Page 381-386, LYMPHEDEMA: A Concise Compendium of Theory and Practice. Lee, Byung-Boong; Bergan, John; Rockson, Stanley G. (Eds.), 1st Edition, Springer-Verlag, London, UK, 2011
  196. Lee BB, Laredo J, Neville R: Reconstructive surgery for chronic lymphedema: a viable option, but. *Vascular* 2011;19 (4):195-205.
  197. Lee BB, Laredo J, Neville R: Current Status of Lymphatic Reconstructive Surgery for Chronic Lymphedema: It Is Still an Uphill Battle! *Int J Angiol* 2011;20(2): 73-79.
  198. Babb RR, Spittell JA Jr, Martin WJ, Schirger A. Prophylaxis of recurrent lymphangitis complicating lymphedema. *JAMA*. 1966;195(10):871-3.
  199. Campisi C, Boccardo F, Campisi CC, Ryan M. *Reconstructive microsurgery for lymphedema: while the early bird catches the worm, the late riser still benefits*. *J Am Coll Surg*. 2013;216:506-7
  200. Papendieck, C.M.: Lymphatic dysplasias in Pediatrics. *Inter Angiol* 1999;18:6-9
  201. Pardini M, Bonzano L, Roccatagliata L, Boccardo F, Mancardi G, Campisi C. Functional magnetic resonance evidence of cortical alterations in a case of reversible congenital lymphedema of the lower limb: a pilot study. *Lymphology* 2007;40 (1):19-25.
  202. Kim DI, Lee BB, Huh S, Lee SJ, Hwang JH, Kim YI. Excision of subcutaneous tissue and deep muscle fascia for advanced lymphedema. *Lymphology* 1998;31:190-194.
  203. Dellon AL, Hoopes JE. The Charles procedure for primary lymphedema. *Plas. & Reconstr. Surg* 1977;60:589-92.
  204. Lee BB, Laredo J, Neville R: Contemporary indication and controversy on excisional surgery. Chapter 49, Section X - Surgical treatment - Excisional/Cytoreductive Surgery Page 403-408, LYMPHEDEMA: A Concise Compendium of Theory and Practice. Lee, Byung-Boong; Bergan, John; Rockson, Stanley G. (Eds.), 1st Edition, Springer-Verlag, London, UK, 2011
  205. Guidelines 6.4.0. on medical and physical therapy. page 663. Chapter 60, Handbook of Venous Disorders: Guidelines of the American Venous Forum, 3rd Edition; Gloviczki, P., Ed; A Hodder Arnold: London, UK. 2009.
  206. Fife CE, Carter MJ. Lymphedema in the morbidly obese patient: unique challenges in a unique population. *Ostomy Wound Manage*. 2008;54:44-56.
  207. Dean SM, Zirwas MJ, Horst, AV . Elephantiasis nostras verrucosa: An institutional analysis of 21 cases. *Journal of the American Academy of Dermatology*, 2011;64(6):1104-1110.
  208. Fernandes LB, Fleury Jr LFF. Comparative dermatology: elephantiasis nostra in verrucous form comparable to coral. *Anais brasileiros de dermatologia*. 2011;86(4), 825-826.
  209. Iwao, F., Sato-Matsumura, K. C., Sawamura, D., & Shimizu, H. Elephantiasis nostras verrucosa successfully treated by surgical debridement. *Dermatologic surgery*. 2011 ;30(6) : 939-941.
  210. Kaposi M. *Leçons sur les Maladies de la Peau*, Masson, Paris, 1881. French translation of *Pathologie und Therapie der Hautkrankheiten in vorlesungen*, Wien-Lepzig, Wien, 1880. pp 125-127.
  211. de Godoy JMP, Azoubel LM, de Fátima Guerreiro Godoy M. Surgical treatment of elephantiasis of the feet in congenital lymphedema to facilitate the use of a compression mechanism. *Int J Gen Med*. 2010;3:115-8.
  212. Bergard SC, Narayanan V. Elephantiasis nostras verrucosa of the pannus. *J Gen Intern Med*. 2011;26(7):810-12.
  213. Mendoza N, Li A, Gill A, Tying S. Filariasis: diagnosis and treatment. *Dermatol Ther*. 2009;22(6):475-90.
  214. Korevaar DA, Visser BJ. Podoconiosis, a neglected topical disease. *Neth J Med* 2012;70:210-14
  215. Davey G, Tekola F, Newport MJ. Podoconiosis: non-infectious geochemical elephantiasis. *Trans R Soc Trop Med Hyg*. 2007;101(12):1175-80.
  216. Padmasiri E, Montresor A, Biswas G, Desilva N. Controlling lymphatic filariasis and soil-transmitted helminthiasis together in South Asia: opportunities and challenges. *Trans R Soc Trop Med Hyg*. 2006;100(9):807-10.
  217. Andrade, M. Lymphatic Filariasis. *Problems in General Surgery* 2001;18:79-84.
  218. Olszewski, W. Infection in Lymphedema: A Concise Compendium of Theory and Practice. Lee BB, Bergan J, Rockson SG (eds.), Springer London, 2011, pp 207-216
  219. Prica S, Donati OF, Schaefer DJ, Peltzer J. Genital elephantiasis: reconstructive treatment of penoscrotal lymphoedema with a myocutaneous M. gracilis flap. Experiences from a District Hospital in Ethiopia. *Handchir Mikrochir Plast Chir*. 2008;40(4):272-8.
  220. Tenhagen M, Lodewijk L, Cense HA, Busch ORC. Clinical appearance and management of massive localized lymphedema in morbidly obese patients: report of 2 cases. *Updates Surg*. 2012 Oct 16.
  221. Champaneria MC, Workman A, Kao H, Ray AO, Hill M. Reconstruction of massive localised lymphoedema of the scrotum with a novel fasciocutaneous flap: A rare case presentation and a review of the literature. *JPRAS* 2013;66(2):281-6
  222. Damstra RJ, Voesten HGJM, Klinkert P, Brorson H. Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer. *Br J Surg*. 2009;96(8):859-64.
  223. Brorson H, Fressero C, Ohlin k, Svensson B. Liposuction normalizes elephantiasis of the leg – a prospective study with a 6 year follow-up. *Lymphology*. 2010;43:105-7.
  224. Brorson H, Ohlin K, Olsson G, Nilsson M. Adipose

- tissue dominates chronic arm lymphedema following breast cancer: an analysis using volume rendered CT images. *Lymphat Res Biol.* 2006;4(4):199-210.
225. Zouboulis CC, Biczó S, Gollnick H, Reupke HJ, Rinck G, Szabó M, *et al.* Elephantiasis nostras verrucosa: beneficial effect of oral etretinate therapy. *Br J Dermatol.* 1992;127(4):411-6.
226. Polat M, Sereflican B. A case of elephantiasis nostras verrucosa treated by acitretin. *J Drugs Dermatol.* 2012;11(3):402-5.
227. Saurat JH. [Acitretin (RO 10-1670). A successor of etretinate?]. *Ann Dermatol Venereol.* 1988;115(8):849-52.
228. Bunke N, Brown K, Bergan J. Phlebolymphe-meda: usually unrecognized, often poorly treated. *Perspect Vasc Surg Endovasc Ther.* 2009;21(2):65-68.
229. Weissleder H, Waldermann F, Kopf W. Familial venous dysplasia and lymphedema. *Z Lymphol.* 1996;20(1):36-39.
230. Mortimer PS. Evaluation of lymphatic function: abnormal lymph drainage in venous disease. *Int Angiol.* 1995;14(3 Suppl 1):32-35.
231. Klippel M, Trenaunay J. Du noeuv variqueux et osteo-hypertrophique. *Arch Gén Méd.* 1900;3:641-672
232. Lee BB, Villavicencio L. General considerations: congenital vascular malformations. In: Cronenwett JL, Johnston KW, eds. *Rutherford's Vascular Surgery.* 7th ed. Philadelphia: Saunders Elsevier; 2010:1046-1064; Section 9. Arteriovenous Anomalies.
233. Lee BB. Invited Editorial: Klippel-Trenaunay syndrome: is this term still worthy to use? *Acta Phlebolog.* 2012;13:83-5
234. Raju S, Furrh JB 4th, Neglén P. Diagnosis and treatment of venous lymphedema. *J Vasc Surg.* 2012 Jan;55(1): 141-9.
235. Chopra K, Tadisina KK, Brewer M, Holton LH, Banda AK, Singh DP. Massive Localized Lymphedema Revisited: A Quickly Rising Complication of the Obesity Epidemic. *Ann Plast Surg.* 2013 May 30. [Epub ahead of print] PubMed PMID:23722582.
236. Raju S, Owen S Jr, Neglen P. Reversal of abnormal lymphoscintigraphy after placement of venous stents for correction of associated venous obstruction. *J Vasc Surg.* 2001;34(5): 779-784.
237. Szuba A, Razavi M, Rockson SG. Diagnosis and treatment of concomitant venous obstruction in patients with secondary lymphedema. *J Vasc Interv Radiol.* 2002;13(8):799-803.
238. Bull RH, Gane JN, Evans JE, Joseph AE, Mortimer PS. Abnormal lymph drainage in patients with chronic venous leg ulcers. *J Am Acad Dermatol.* 1993;28(4):585-590.
239. Silva JH, Janeiro-Perez MC, Barros N, Vieira-Castiglioni ML, Novo NF, Miranda F. Venouslymphatic disease: lymphoscintigraphic abnormalities in venous ulcers. *J Vasc Bras.* 2009;8(1):33-42.
240. Franzeck UK, Haselbach P, Speiser D, Bollinger A. Microangiopathy of cutaneous blood and lymphatic capillaries in chronic venous insufficiency. *Yale J Biol Med.* 1993;66(1):37-46.
241. Bollinger A, Partsch H, Wolfe JHN. *The Initial Lymphatics.* Thieme Stratton Inc New York, 1985
242. Tiedjen KU. Detection of lymph vessel changes in venous diseases of the leg using imaging procedures. *Z Lymphol.* 1989;13(2):83-87.
243. Pannier F, Hoffmann B, Stang A, Jöckel K.-H, Rabe E. Prevalence of Stemmer's sign in the general population. Results from the Bonn Vein Study. *Phlebologie* 2007; 36: 289-292
244. Lee BB, Baumgartner I, Berlien HP, Bianchini G, Burrows P, Do YS, Ivancev K, Kool LS, Laredo J, Loose DA, Lopez-Gutierrez JC, Mattassi R, Parsi K, Rimon U, Rosenblatt M, Shortell C, Simkin R, Stillo F, Villavicencio L, Yakes W. Consensus Document of the International Union of Angiology (IUA)-2013. Current concept on the management of arterio-venous management. *Int Angiol.* 2013 Feb;32(1):9-36.
245. Ziyeh S, Spreer J, Rossler J, Strecker R, Hochmuth A, *et al.* Parkes Weber or Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography. *Eur Radiol.* 2004;14(11):2025-2029.
246. Courivaud D, Delerue A, Delerue C, Boon L, Piette F, Modiano P. Familial case of Parkes Weber syndrome. *Ann Dermatol Venereol.* 2006;133(5):445-7.
247. Lee BB, Laredo J, Lee SJ, Huh SH, Joe JH, Neville R. Congenital vascular malformations: general diagnostic principles. *Phlebology.* 2007;22(6):253-7.
248. Vollmar JF, Voss E. Vena marginalis lateralis persistens – die vergessene Vene der Angiologen. *Vasa.* 1979;8:192-4.
249. Kim YW, Lee BB, Cho JH, Do YS, Kim DI, Kim ES. Haemodynamic and clinical assessment of lateral marginal vein excision in patients with a predominantly venous malformation of the lower extremity. *Eur J Vasc Endovasc Surg.* 2007;33(1):122-127.
250. Lee BB. Marginal vein is not a simple varicose vein: it is a silent killer! Review. *Damar Cer Derg* 2013;22(1): 4-14.
251. Mattassi R, Vaghi M: Management of the marginal vein: current issues. *Phlebology* 2007; 22: 283-286
252. Lee BB, Laredo J, Neville R: Embryological background of truncular venous malformation in the extracranial venous pathways as the cause of chronic cerebrospinal venous insufficiency. *Int Angiol* 2010;29(2):95-108
253. Lee BB. Venous embryology: the key to understanding anomalous venous conditions. *Phlebology.* 2012;19(4):170-181.
254. Loose DA. Contemporary treatment of congenital vascular malformations. In: Dieter RS, Dieter RA Jr, Dieter RA III, eds. *Peripheral Arterial Disease.* New York: McGrawHill Medical; 2009. pp.1025-1040.
255. Loose DA. Surgical management of venous malformations. *Phlebology.* 2007;22(6):276-282.
256. Loose DA. Surgical treatment of predominantly venous defects. *Semin Vasc Surg.* 1993;6(4):252-259.
257. Lee BB, Laredo J, Kim YW, Neville R. Congenital vascular malformations: general treatment principles. *Phlebology.* 2007;22(6):258-263.
250. [www.who.int/whosis/icd10/](http://www.who.int/whosis/icd10/)
251. Allen, EV, EA Hines. Lipedema of the legs: a syndrome characterized by fat legs and orthostatic edema. *Mayo Clin. Proc* 1940;15:184-7.
253. Földi E, Földi M. [Das Lipödem] in Földi M, Kubik S eds, *Lehrbuch der Lymphologie, 5nd edn, Chapt 9.* München-Jena:Gustav Fischer, 2002:449-58.
254. Langendoen SI, Habbema L, Nijsten TEC, Neumann HAM. Lipoedema: from clinical presentation to therapy. A review of the literature. *Br J Dermatol* 2009;161:980-6.
255. Fife CE, Maus EA, Carter MJ. Lipedema a frequently misdiagnosed and misunderstood fatty deposition syndrome. *Adv Skin Wound Care.* 2010;23:81-92
256. Forner-Cordero I, Szolnoky G, Forner-Cordero A, Kemény L. Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review. *Clin Obstetr.* 2012;2:86-95.
257. Chen S, Hsu SD, Chen TM, Wang HJ. Painful fat syndrome in a male patient. *Br J Plast Surg* 2004; 57: 282-6.

258. Siems W, Grune T, Voss P, Brenke R. Anti-fibrosclerotic effects of shock wave therapy in lipedema and cellulite. *Biofactors* 2005; 24: 275-82.
259. Bano G, Mansour S, Brice G, Ostergaard P, Mortimer PS, Jeffery S, Nussey S. Pit-1 mutation and lipoedema in a family. *Exp Clin Endocrinol Diabetes* 2010;118:377-80.
260. Child AH, Gordon KD, Sharpe P, Brice G, Ostergaard P, Jeffery S, *et al*. Lipoedema: an inherited condition. *Am J Med Genet Part A* 2009;152:970-6.
261. Suga H, Araki J, Aoi N, Kato H, Higashino T, Yoshimura K. Adipose tissue remodeling in lipedema: adipocyte death and concurrent regeneration. *J Cutan Pathol* 2009;36:1293-8.
262. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. *J Leukoc Biol*. 2010; 88:33-39.
263. Berry R, Rodehoffer MS. Characterization of the adipocyte cellular lineage *in vivo*. *Nat Cell Biol*. 2013;15:302-308)
264. Schmeller W, Hartwig D: [Lipedema and congenital analbuminemia: a rare combination] *LymphForsch* 2012;16:58-63 .
265. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. *Nat Genet*. 2005;37:1072-1081.
266. Zampell JC, Aschen S, Weitman ES, Yan A, Elhadad S, De Brot M, Mehrara BJ. Adipogenesis in response to lymphatic fluid stasis is associated with a marked mononuclear cell inflammatory response. *Plast Reconstr Surg*. 2012;129:825-834.
267. Harwood CA, Bull RH, Evans J, Mortimer PS. Lymphatic and venous function in lipedema. *Br J Dermatol*.1996;134:1-6.
268. Meier-Vollrath I, Schneider W, Schmeller W: Das Lipödem: neue Möglichkeiten der Therapie. *Schweiz Med Forum* 2007;7:150-5.
269. Schingale FJ. Lipoedema. In: *Lymphoedema, Lipoedema: A guide for those effected*. Schlütersche: Hannover, 2003, pp 64-71.
270. Herpertz U. Adipositas-Diagnostik in der Lymphologie. *Lymph Forsch* 2009;13:90-3
271. Streeten DH. Idiopathic edema. Pathogenesis, clinical features, and treatment. *Endocrinol Metab Clin North Am* 1995;24:531-47.
272. Szolnoky G, Nagy N, Kovács RK, Dósa-Rácz E, Szabó A, Bársony K, Balogh M, Kemény L. Complex decongestive physiotherapy decreases capillary fragility in lipedema. *Lymphology* 2008;41:161-6.
273. Szolnoky G, Nemes A, Gavallér H, Forster T, Kemény L. Lipoedema is associated with increased aortic stiffness. *Lymphology*. 2012;45:71-9.
274. Schmeller W, Meier-Vollrath I. Schmerzen beim Lipödem. Versuch einer Annäherung. *Lymph Forsch* 2008;12(1):7-11.
275. Szolnoky G, Varga E, Varga M, Dósa-Rácz É, Kemény L. Complex decongestive physiotherapy decreases pain intensity in lipedema. *Lymphology* 2011;44:178-82.
276. Naouri M, Samimi M, Atlan M, Perrodeau E, Vallin C, Zakine G *et al*. High resolution cutaneous ultrasonography to differentiate lipoedema from lymphoedema. *Br J Dermatol* 2010; 163:296-301.
277. Monnin-Delhom ED, Gallix BP, Achard C, Bruel JM, Janbon C. High resolution unenhanced computed tomography in patients with swollen legs. *Lymphology*. 2002;35:121-8.
278. Dimakakos PB, Stefanopoulos T, Antoniadis P. MRI and ultrasonographic findings in the investigation of lymphedema and lipedema. *Int Surg* 1997;82:411-6.
279. Brauer WJ. Altersbezogene Funktionslymphszintigraphie beim Lipödem und Lipolymphödem. *Lymph Forsch* 2000;4: 74-7.
280. Amann-Vesti BR, Franzeck UK, Bollinger A. Microlymphatic aneurysms in patients with lipedema. *Lymphology* 2000;134:170-5.
281. Lohrmann C, Foeldi E, Langer M. MR imaging of the lymphatic system in patients with lipedema and lipo-lymphedema. *Microvasc Res* 2009;77:335-9.
282. Deri G, Weissleder H. Vergleichende prä- und posttherapeutische Volumenmessungen in Beinsegmenten beim Lipödem. *Lymph Forsch* 1997;1:35-7.
283. Szolnoky G, Borsos B, Bársony K, Balogh M, Kemény L. Complete decongestive physiotherapy of lipedema with or without pneumatic compression: a pilot study. *Lymphology* 2008;41:50-2.
284. Flour M, Clark M, Partsch H, Mosti G, Uhl JF, Chauveau M, Cros F, Gelade P, Bender D, Andriessen A, Schuren J, Cornu-Thénard A, Arkans E, Milic D, Benigni JP, Damstra R, Szolnoky G, Schingale FJ. Dogmas and Controversies in Compression Therapy. Report of an International Compression Club (ICC) meeting, Brussels. *Int Wound J* 2012 Jun 21
285. Schmeller W, Hueppe M, Meier-Vollrath I. Tumescent liposuction in lipoedema yields good long-term results. *Br J Dermatol*. 2012;166:161-8.

*Acknowledgment.*—The authors would like to thank to Professor Wilfried Schmeller (Hanse Klinik, Lübeck, Germany) for his insightful review and essential comments on Lipedema-Differential Diagnosis subchapter, Professor Tiziana Baroncelli (Vascular Center, Prato, Italy) on Diagnostic Evaluation of Lymphedema subchapter, and Dr. Sahar Mansour, (St. George's, University of London, London, UK) for impeccable review on the Genetic issues.

Received on July 15, 2013; accepted for publication on October 11, 2013.

Corresponding author: Byung-Boong (B.B.) Lee, Division of Vascular Surgery, Department of Surgery, George Washington University Medical Center, 22nd and I Street, NW, 6th Floor, Washington, DC 20037 USA.